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ABSTRACT 
 
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF GENETIC 
VARIANTS IN THE HUMAN INDOLEAMINE 2,3-DIOXYGENASE (INDO) 
GENE  
 
Million Arefayene 
 
 
Indoleamine 2,3-dioxygenase (IDO) is a rate limiting enzyme in tryptophan 
catabolism that has been implicated in the pathogenesis of a number of diseases. 
Large interindividual variability in IDO activity in the absence of stimuli and as the 
result of therapy induced changes has been reported. This variability has the potential 
to contribute to susceptibility to disease and to interindividual variability in 
therapeutic response. 
To identify genetic variations that might contribute to interindividual 
variability in IDO activity, we resequenced the exons, intron/exon borders and 1.3 kb 
of the 5’-flanking region of the INDO gene in 48 African-American (AA) and 48 
Caucasian-American (CA) subjects from the Coriell DNA Repository. A total of 24 
INDO variants were identified. Seventeen of these were in exons, introns, or 
exon/intron boundries, while seven were within 1.3 kb upstream of the translation 
start site. Seventeen are novel and 7 were previously identified.  
When transiently expressed in COS-7 or HEK293 cells the amino acid 
sequence change in Arg77His resulted in significant decrease in activity, and it 
reduced the Vmax of IDO. The Arg77His variant and the 9 bp deletion resulted in 
nearly complete loss of enzyme activity and a lack of detectable protein expression.  
 
 vii
The function of the Arg77His variant IDO was restored in a dose dependent 
manner by the heme analog hemin; but there was no associated increase in IDO 
protein. Cellular heme concentration was higher in cells transfected with the wild 
type and Ala4Thr variant constructs, but not in cells transfected with the Arg77His 
variant. The heme synthesis inhibitor, succinylacetone (SA), blocked IDO activity in 
cells transfected with Arg77His.  
We identified 22 putative transcription binding sites within the 1.3 kb 
upstream of the translation start site. Two of the SNPs were located in GATA3 and 
FOXC1 sites. A specific 3-SNP haplotype reduced promoter activity when transiently 
transfected into 2 different cell lines.  
We conclude that there are naturally occurring genetic variants in the INDO 
gene which affect both expression and activity. These results make clear that 
interindividual variability in IDO activity at baseline or in response to therapy may be 
in part due to inherited genetic variability.  
 
Chairman, David Flockhart, M.D., Ph.D. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
Indoleamine 2,3-dioxygenase (IDO) is a cytosolic enzyme that catalyzes the 
oxidation of tryptophan into kynurenine. Its expression and activity have 
demonstrated a large interindividual variability in several clinical studies. This 
variability includes baseline activity, as well as therapy induced changes in IDO 
activity. This variability might contribute to differences in the susceptibility to 
diseases that are influenced by the immune system, such as cancer and autoimmune 
diseases. The responses to several therapies may also be influenced by the level of 
IDO. The source of variability could be a number of possible environmental and 
intrinsic mechanisms. Forexample the mechanism might include exposure to naturally 
occurring compounds, drugs, and carcinogens; however, it is also possible that 
genetic variation may play an important role. The contribution of genetic variation in 
the INDO gene to phenotypic variability is the focus of these studies. A 
comprehensive understanding of the variability in tryptophan metabolism is important 
because it will likely help to predict therapeutic responses, to develop improved 
therapies for the subgroups of patients, and to better understand the role of IDO in 
disease pathogenesis. 
The goals of this dissertation are to identify the genetic variants in the INDO 
gene in human and to determine their functional significance. 
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1.1 Background 
Tryptophan (trp) is the least abundant of all essential amino acids. The major 
metabolic route of tryptophan in mammals is the kynurenine (kyn) pathway. A 
limited amount of trp is used for protein and serotonin synthesis, but in humans, over 
90% of tryptophan catabolism is through the kynurenine pathway 1-3. This pathway 
includes a number of other enzymes that further metabolize kynurenine (Figure 1.1). 
This pathway ultimately leads to the biosynthesis of nicotinamide adenine 
dinucleotide (NAD) (Figure 1.1). 
 
Figure 1.1 Schematic pathway of tryptophan metabolism. 
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There are three different enzymes that metabolize tryptophan into kynurenine: 
• Tryptophan 2,3 dioxygenase (TDO) 
• Indoleamine 2,3 dioxygenase (IDO)  
• Indoleamine 2,3 dioxygenase like protein (INDOL-1) or IDO-2 
Tryptophan 2,3-dioxygenase (TDO, EC 1.13.11.11) was first discovered in rat 
liver extracts 4, 5. The TDO gene is located on the long arm of the human chromosome 
4q31-q23 6. The gene has 12 exons and spans about 17.5 kb of the human genome. 
TDO is a glucocorticoid responsive gene 7. There is one study which showed the 
presence of a glucocorticoid response element in the human TDO promoter starting at 
-11747. While it is well known that TDO mRNA is highly expressed in the liver, its 
expression has also been found in pituitary gland, mammary gland, bladder, colon, 
lung, testis, pancreas and skin (NCBI Unigene Hs.183671).  
Following the identification of TDO, in 1963 a second enzyme was also found 
that catalyzes the oxidative cleavage of tryptophan 8. This non-hepatic tryptophan 
metabolizing enzyme was named D-tryptophan pyrrolase; later, the name was 
changed to indoleamine 2,3-dioxygenase (IDO). The IDO protein is encoded by the 
gene designated as INDO 9. The INDO gene shares no sequence homology with TDO 
10 11; however, like TDO, IDO is also a heme-containing enzyme. 
In humans, INDO is a single copy gene comprised of 10 exons spanning ~15 
kb. It maps to chromosome 8p12-p11 6, 9. Indoleamine 2,3-dioxgyenase (IDO, EC 
1.13.11.42) is a cytosolic heme protein which, together with the hepatic enzyme 
tryptophan 2, 3 dioxygenase (TDO), catalyzes the conversion of tryptophan and other  
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indole derivatives to kynurenines . IDO is first translated as a 45 kDa apoenzyme; 
subsequently, the heme prosthetic group is added to make the holoenzyme (Figure 
1.2). 
 
Figure 1.2 Indoleamine 2,3-dioxygenase gene structure. 
 IDO oxidizes the pyrrole moiety of tryptophan and other indoleamines. In 
some tissues, it is the initial and rate-limiting enzyme of the kynurenine pathway. It is 
a unique enzyme in that it can utilize superoxide anion radical (O2•) as both a 
substrate and a co-factor. The latter role results from the ability of O2•- to reduce  
inactive ferric-IDO to the active ferrous form 11, 12. Antioxidant activity may arise 
from IDO scavenging O2•-, formation of the potent radical scavengers and  
kynurenine pathway metabolites, 3-hydroxyanthranilic acid and 3-hydroxykynurenine 
13. 
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IDO is expressed in a variety of cell types; of particular importance are those 
involved in mediating key steps of an immune response . In many of these cells, IDO 
is known to be induced mainly by interferon-γ (IFN-γ). This induction is usually a 
result of infectious agents or chronic inflammatory disorders 12, 14. Normal induction 
of IDO, and consequently the metabolism of tryptophan along the kynurenine 
pathway, is implicated in a variety of physiological processes. Abnormal induction of 
IDO is implicated in several pathophysiological processes including anti-microbial, 
anti-tumor defense, neuropathology, immunoregulation and antioxidant activity 14. 
IDO is constitutively expressed in healthy tissues with large areas of mucosal surfaces 
(e.g. lungs, gut, and fetal-maternal unit during pregnancy), in the epididymis, and in 
the thymus 15. In healthy tissues that are continuously exposed to antigens, such as 
mucosal surfaces of the gut, lung, and uterus during pregnancy, IDO expression is 
normally high 16.  
The first suggestion that IDO expression regulates T cell responses came from 
studies on human macrophages that suppressed T cell proliferation 17. Two 
mechanisms have been proposed to explain the inhibitory effect of IDO on T-cell 
function. First, IDO activity creates a tryptophan depleted microenvironment limiting 
the proliferation of T-cells17. This study prompted further work that revealed a critical 
role for IDO in preventing fetal rejection by maternal T-cells during pregnancy 18. 
Second, downstream tryptophan metabolites have inhibitory effects on T-cells  
proliferation and function19. Today, several studies support the hypothesis that cells 
expressing IDO regulate T cell-mediated immune responses in inflammatory diseases, 
transplant rejection, pregnancy, and cancer 17, 20-22. 
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Recent studies have revealed a critical role of IDO in the regulation of normal 
immune function; specifically IDO appears to have a role in the local control of 
tolerance vs. rejection of tissues with foreign antigens 14. When T-cells migrate into 
tissues with low tryptophan concentrations and high concentrations of tryptophan 
degradation products which is caused by IDO, the T-cells undergo growth arrest 
and/or apoptosis 23. This mechanism results in the localized suppression of T-cell 
responses and consequently leads to immune tolerance 24-26. 
A third enzyme, which also metabolizes tryptophan has recently been 
discovered 27, 28. Because of the similarity of the gene products and their activities, the 
gene has been named indoleamine 2,3-dioxygenase -like protein (INDOL1). The 
INDOL1gene maps to chromosome 8p11.21. It has 11 exons. When the predicted 
protein is aligned with INDO, it has 43% amino acid identity 28. The INDOL1 gene is 
located 3’ to the INDO gene and separated by 6.5 kb 27. INDO and INDOL1to have 
arisen by gene duplication before the origin of the tetrapods. In the mice, the  
expression of INDOL1 is highest in the kidney, followed by epididymis and liver 27, 29. 
The identification of INDOL1 may help to explain the regulation of the diversity of 
physiological and pathophysiological processes in which the kynurenine pathway is 
involved 28.  
 
 1.1.2 Indoleamine 2,3-dioxygenase and disease 
Degradation of the essential amino acid tryptophan is now recognized to play 
an important role in immunity and in a growing list of pathophysiological conditions.  
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 This rate limiting enzyme in tryptophan catabolism appears to have an active role in 
the pathogenesis of a number of diseases 30-43. Several of them are described in the 
following sections. 
 
1.1.2.1 Immune tolerance and cancer 
The first clue to a role for IDO in immune regulation was the discovery that 
expression of the INDO gene is strongly induced at the transcription level by the 
macrophage activating cytokine interferon-γ 44-47. The connection between elevated 
urinary tryptophan metabolites and bladder cancer was first reported in the 1950’s 48. 
This discovery prompted an interpretation of long-standing clinical observations 
indicating that tryptophan metabolites are elevated in the urine of cancer patients 49-52. 
Consistent with this idea, it was reported later that IDO activity was elevated in lung 
tumors 53. Since then, elevated levels of IDO generated tryptophan metabolites have 
been associated with a number of malignancies 41, 54. This phenomenon was initially  
thought to be a tumoricidal consequence of IFN-γ, which stimulates expression of 
IDO in cells 55. 
Several mechanisms of tumor-induced immunosuppression have been 
proposed, and each is likely to contribute to the overall suppression 56. Using IDO 
protection mechanism during normal pregnancy as a starting point, a number of 
researchers hypothesized that cancer cells may use the same mechanisms, to evade 
immunosuppression. The mechanisms include impaired antigen presentation 57, 58, 
expression of death ligands 59 and secretion of soluble inhibitory factors by the 
tumors 60. This suppression appears to be mediated through effects on both T-cells  
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and antigen presenting cells 61. The first evidence was offered in 2002 that the 
specific IDO inhibitor 1-methyl tryptophan (1-MT) could partly retard the growth of 
mouse melanoma cells engrafted onto a syngenic host 62. It is increasingly clear that 
tumors induce tolerance to their own antigens. Tumors can also evade local immune 
destruction despite the systemic presence of tumor reactive T-cells 63.  
IDO mediated tryptophan catabolism may participate in immune tolerance in 
two ways. First, it may induce tolerance by affecting the ability of host APCs to 
present tumor antigens. Second, it may directly suppress immune effector cells in the 
tumor microenvironment 64-66. This strategy appear to utilize a mechanism that 
normally exists to prevent maternal immune response to paternal fetal antigens 67.  
The interaction between developing tumors and the immune system is 
complex and dynamic. In vitro, T-cells and antigen presenting cells are capable of 
mounting tumor-specific responses if primed with tumor lysates 68, 69. In vivo, patients 
often have tumor-reactive T-cells. Cancer vaccines using tumor specific antigens are 
also capable of generating specific responses 70. However, despite this competency of 
the immune system and the existence of antigens on tumor cells, there is still a lack of 
effective immune response in untreated patients and even in many receiving cancer 
vaccines 71.  
The recruitment of IDO expressing cells to tumors and draining lymph nodes 
may also be a mechanism of immunosuppression by tumors. In one study, 25 of 36  
lymph nodes draining human melanoma tumors contained elevated numbers of IDO 
expressing cells 72. In another study, an abnormal accumulation of IDO expressing  
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cells was observed in sentinel lymph nodes of melanoma patients, even in the absence 
of detectable tumor cells 73.  
Macrophages frequently express high levels of IDO and have the ability to 
suppress T-cell proliferation by the rapid degradation of trp 72, 74. In human breast 
cancers, high levels of tumor-associated macrophages in the tumors correlate with a 
poor prognosis 75. Part of this effect is thought to be caused by the secretion of 
various tumor stimulating growth factors 76, 77. However, the expression of IDO and 
metabolism of tryptophan to suppress the T-cell response may be another mechanism 
by which macrophages contribute to breast cancer progression and a poor prognosis. 
The cancer cells themselves may also be a source of IDO expression. IDO expression 
was detected in 24 of 25 types of cancers cells 78. IDO expression has been shown to 
be induced by IFN-γ in several types of cancer cells, such as breast, ascites tumors, 
colon cancer and melanoma cancer cells 79. In inflammation, IFN-γ is secreted at the 
site of inflammation to help induce a T-cell response against the infected and/or 
foreign cells. However, in tumors, the IFN-γ induced IDO expression in cancer cells 
appears to provide a mechanism for the cancer cells to escape the T-cell mediated 
elimination. The failure of the immune system to respond protectively to the tumor 
antigens contributes to the progression of cancer to a life-threatening disease 80. 
 
1.1.2.2 Organ transplant 
IDO has been shown to play an important role in transplantation immunology 
81. One of the main goals in transplantation immunology is to achieve immune 
toleration against allo-antigens; however immunity against pathogens needs to be  
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preserved. IDO mediated tryptophan metabolism appears to be a induce tolerance in 
organ transplantation 82. Potent IDO mediated immunoregulation acts locally in the 
site of antigens. Therefore, locally manipulating IDO mediated immune regulation 
appears to bepotentailly important therapeutic tool. While experimental systems 
including in vitro and animal studies support the role for IDO mediating 
transplantation tolerance, its relevance to human transplantation immunology remain 
to be defined 83. To date, evidence to support a therapeutic role of IDO for tolerance 
induction in clinical organ transplantation is limited 83. In vivo studies showed that 
systemic blockade of IDO with a competitive IDO inhibitor 1-MT after lung 
transplantation resulted in spontaneous proliferation of T-cells in lung and caused 
pulmonary inflammation. It has been shown that, over expression of IDO in lung 
transplants abrogates acute allograft rejection 84. Survival of transplanted pancreatic 
islet cells 85 and cardiac allograft 86 is also prolonged by overexpression of IDO. 
In conclusion, a better understanding of the implications of IDO activity on 
different cell types will allow a more focused approach to determine if IDO has a role 
in generating transplantation tolerance. 
 
1.1.2.3 Depression 
 
Over the last several decades, recombinant preparations of the interferon-α 
(IFN-α) have played an increasingly important role in the treatment of a number of 
medical conditions. Two of the most significant are chronic viral hepatitis and several 
malignancies. IFN-α binds to specific membrane bound receptors and stimulates the 
expression of several genes. The products of these genes, either individually or  
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coordinately, mediate IFN-α immunoregulatory activity. In addition to their 
therapeutic effects, IFN-α also frequently causes dose-dependent neuropsychiatric 
adverse effects. For example, IFN-α treatment results in major depressive disorders in 
30–50% of patients 87, 88. In addition to their effects on quality of life, these adverse 
effects also increase the risk of treatment discontinuation; consequently, they can 
increase the risk of poor treatment outcome 89-92. Therefore, it is of paramount 
importance to better understand why some patients are at increased risk for 
depression during treatment with IFN-α.  
IDO overexpression would be expected to reduce the synthesis of brain 
serotonin (5-HT), which may play a role in the development of depressive symptoms. 
In fact, IFN-α administration has been shown to suppress 5-HT concentration in brain 
and serum of patients 92-94. The link between increased IDO activity and tryptophan 
depletion has been well established 95. The results from these studies suggested that 
reduced availability of tryptophan in patients undergoing interferon therapy could be 
related to the depression 87, 96. It is also known that IFN-α enhances IDO gene 
expression and activity, presumably indirectly through a 15 kD protein which is a  
product of IFN-α stimulated monocytes and lymphocytes 97. It is therefore possible 
that the neuropsychiatric symptoms observed in some patients could be because of 
several pathophysiological factors. Indeed, many studies have documented different 
rates of depression in patients with a wide range of medical disorders. They include 
the conditions against which IFN-α is most typically directed, such as cancer and 
viral infections 93. The different rates of depression observed after the IFN-α 
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treatment could be the reflection of the variability in the IFN-α mediated activation of 
IDO 98. 
In summary, to investigate the therapeutic use of IDO inhibitors would be of 
great value, given that IDO appearse intimately involved in immuneregulation in 
transplantation. Genetic variations in one or more of the genes involved in IDO 
regulation, or other genes that might affect tryptophan metabolism pathway, could 
account for variable susceptibility to different diseases. These variations could 
contribute to the interindividual difference in tumor metastasis, immune tolerance 
development and variable interferon responses.  
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 CHAPTER 2   
 GENETIC VARIABILITY 
 
2.1 What is a genetic polymorphism? 
 
Genetic polymorphisms occur in multiple forms; they include single 
nucleotide polymorphisms (SNPs), complete gene deletions, gene duplications, and 
genetic translocations where portions of similar genes are combined creating a new 
gene hybrid. Polymorphisms are responsible for the many phenotypic differences 
between people. Some genetic changes are very rare while others are common in 
populations. By far the most frequent genetic variations in the human population are 
SNPs. SNPs involve a single nucleotide change at one specific position. Each of these 
changes in the gene sequence introduces a variant form of the gene into the 
population gene pool. Each different sequence at a locus is designated as an allele. 
Some standards suggest that a gene variant can be classified as an allele when the 
frequency of the variation is ≥ 1% 99. Such changes are common enough to be 
considered as normal variations in the DNA.  
SNPs can result in a variety of changes in the expressed protein function. The 
specific effect depends upon where the polymorphism occurs in the overall gene 
structure. Single base substitutions are classified into silent substitutions 
(synonymous; sSNPs) and missense (nonsynonymous; nsSNPs). Synonymus 
variations did not change the coding sequence for example, AGA →AGG, both 
encode the amino acid arginine. Nonsynonymous is a base substitution that alters the  
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codon specifying a different amino acid, e.g. AGA→GGA, would change an amino 
acid from an arginine to a glycine.  
A major interest in human genetics is to determine whether a genetic 
polymorphism in a gene affects its protein product and consequently, impacts the 
carrier's health. Amino acid substitutions currently account for approximately half of 
the known gene lesions responsible for human inherited disease 100. Therefore, it is 
important to determine whether genetic variants that affect the amino acid sequence 
of a gene product can alter protein function and contribute to disease. Genetic 
variations in the coding and regulatory regions are believed to have the highest impact 
on phenotype. Variations within the intron regions are typically silent; however, if the 
variant is in nucleotides that are critical for RNA splicing such variants can also lead 
to altered protein function.  
 
2.2 The potential effect of genetic variation in protein quality control, 
degradation and aggressome formation. 
Protein quality control is a basic cellular phenomenon through which 
abnormal proteins become eliminated. All cells are equipped with a proteolytic 
apparatus that eliminates damaged, misfolded and incorrectly assembled proteins 101-
103. Abnormal proteins can occur during cellular stress, or can be due to a variant that 
could lead to a none functional protein 102-105. Several mechanisms could potentially 
explain decreased protein levels as a result of inherited alterations in encoded amino  
acid sequence. For example, some SNPs cause altered amino acid sequence which 
resulted accelerated degradation of the variant protein 106, 107. Aggressomes are 
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manifestations of reduced cellular aggregate degradation in the endoplasmic 
reticulum and cytoplasmic compartments, respectively, and are often associated with 
disease 108, 109 (Figure 2.1). When the production of aggregation-prone proteins 
exceeds the cell’s (or organelle’s) capacity to eliminate them cellular aggregates form 
102. Cellular pathways that resolve these aggregates exist, but appear to have limited 
capacities. The main engine of cytoplasmic proteolysis, the 26S proteasome, requires 
that substrates be unfolded to gain access to the active site; consequently, it is 
relatively ineffective at degrading aggregated proteins102.  
 
 
 
Figure 2.1 Protein degradation and aggressome formation. 
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2.3 Indoleamine 2,3-dioxygenase and pharmacogenetics  
 
The field of pharmacogenetics is concerned with the ability of genetic 
variations (polymorphisms) to alter drug concentrations and responses. Genetic 
differences in the drug metabolizing enzymes cause the same dose of drug to yield 
varying systemic concentrations in different individuals. Variations in systemic drug 
concentrations help to explain why some patients respond well to drugs, but some do 
not. A drug might be toxic to one individual and not another. The medical community 
has been aware for 50 years of these different responses and of the activities of a 
limited number of enzymes that are involved in the metabolism of endogenous and 
exogenous compounds. Examples include the butyrylcholinesterase genetic 
polymorphism that was initially recognized as a result of decreased metabolism and 
the prolonged effect of the muscle relaxant succinylcholine 110. Another early 
example was inherited variation in N-acetylation catalyzed by N-acetyltransferase 2 
(NAT2), a phase II drug-metabolizing enzyme that catalyzes the biotransformation of 
isoniazid (the antituberculosis agent) 111 and hydralazine (the antihypertensive agent) 
112. Included among pharmacogenetically relevant proteins that have been studied 
with regard to the functional effects of nsSNPs is another phase II drug-metabolizing 
enzyme thiopurine S-methyltransferase (TPMT)113. 
Genetic variations in DNA can alter the amino acid sequences of proteins or 
alter how much protein is expressed. Such variants differ from each other by 
structural changes and can include change in amino acid sequences, rearrangement of 
genes, and deletion of gene sections.  
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Genetic polymorphisms in a number of genes have been studied in an effort to 
clarify the disparity in drug response among individuals. The body of literature 
addressing polymorphisms that influences IDO expression and activity is also 
increased in the past years.  
 
2.4 Genetic polymorphism and tryptophan metabolism 
Tryptophan metabolism occurs via both hepatic (TDO) and majority extra-
hepatic (IDO and IDO2 or INDOL1) pathways. Although these pathways share many 
enzymes, the first and rate-limiting step in each pathway is carried out by three 
different enzymes: tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 
(INDO) and indoleamine 2,3-dioxygenase like protein IDO2 (INDOL1). Over the 
course of many years, extensive research has led to better understanding of the 
important biological functions of these enzymes. One of the tasks that now lie ahead 
is linking the genetic variations in these enzymes with variable human responses in 
different disease states. 
2.4.1 Polymorphisms in TDO 
There is a single report of a TDO genetic polymorphism in the coding region. 
This nsSNP, (A238T; rs11541501, NCBI dbSNP leads to an amino acid change 
Gln58His. As a result of a nucleotide change is on exon 3 (NM_005651.1). Although 
this genetic polymorphism in TDO was submitted to the NCBI database in 2003, 
there is still no functional or population frequency data available. There are four TDO 
promoter variants reported. One of them (rs3755910) has been linked with autism 114.  
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Association studies of TDO variants also revealed a significant association of two 
SNPs in intron 6 with Tourette syndrome, attention deficit hyperactivity disorder, and 
drug dependence 115, 116. 
 
2.4.2 Indoleamine 2,3-dioxygenase genetic polymorphism  
A total of 43 INDO genetic variants have been reported in the NCBI SNP 
database. Six of them are coding variants and are listed in Table 2.1. There are 26 
intronic and eleven 5’flanking region SNPs. 
Table 2.1 Coding variants of INDO gene currently described in the SNP data base. 
SNP ref ID Position Nucleotide change @Alteration# 
rs35059413 Exon 1 G  >  A Ala4Thr 
rs35099072 Exon 3 G  >  A Arg77His 
rs1245877 Exon 4 G  >  A Arg105Lys 
rs4463407 Exon 4 T  >  G IIe107Ser 
rs12545878 Exon 4 G  >  A Lys116Lys 
rs34155785 Exon 6 G  insertion Codon shift 
@ The SNP ref ID are assigned by NCBI SNP database at: 
http://www.ncbi.nlm.nih.gov/sites/entrez , # the amino acid position is relative to the 
403 amino acids in the NCBI gene bank protein reference: Version NP_002155 
 
2.4.3 Indoleamine 2, 3 dioxygenase-like protein (INDOL1) genetic polymorphism 
Based on the Ensemble Human Gene variation Report for INDOL1 released 
December 2006, (ENSG00000188676) there are 7 coding variations. These variations 
include 3 nonsynonymous SNPs. Two of the nonsynonumus SNPs reduced enzymatic 
activity 90% in T-REX cells. The third variant T-A SNP affecting Y359 generated a 
premature stop codon (Y359X), which completely abolished IDO2 activity 29.  
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Interestingly, these SNPs were commonly found in human genomic DNAs in public 
databases. The C-T SNP has the highest prevalence in individuals of European 
descent. The T-A SNP is the highest in individuals of Asian descent. Neither SNP 
was as frequent in individuals of African descent. About 50% of individuals of 
European or Asian descent and 25% of individuals of African descent may lack 
functional IDO2 alleles.  
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Chapter 3 
hypothesis and specific aims 
 
Central hypothesis  
Genetic polymorphisms in the coding and promoter region of the INDO gene 
cause alterations in IDO expression and/or activity.  
 
Specific Aims 
Aim 1: To identify IDO genetic polymorphisms in the coding region that affect 
enzyme expression and/or activity and to evaluate the mechanisms by which these 
variants influence activity.  
 The working hypothesis for this aim is that the genetic variations in the IDO 
gene cause functional changes in IDO expression and/or activity. Since IDO plays a 
key role in the development of tolerance, we have hypothesized that genetic variation 
in the IDO gene may be at least partly responsible for the variable IDO expression.  
 The Rationale for this research is that a better understanding of the 
interindividual variability in IDO activity would likely help understand tumor 
development and variability in responses to cytokine therapy, partially with interferon 
gamma. Once this information is available, it will be possible to rationally design 
more effective treatment strategies that incur a minimum of adverse drug effects and 
allow better compliance to cytokine therapy. Genetic variation of INDO gene may 
also be valuable in interperating the clinical responses to IDO inhibiting drugs.  
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Aim 2: To identify genetic variants in the IDO promoter and to assess their 
functional significance. 
Working hypothesis: Genetic variations in the IDO promoter cause functional 
changes in IDO expression.  
RATIONALE: The evidence vailable shows a large variability in IDO 
expression and activity in tumors and therapy interferon –gamma induced IDO 
expression. Since this variability may be due to INDO promoter variants, we assessed 
genetic variants in the 5’-flanking region of IDO promoter using a luciferase reporter 
gene. This research will provide the foundation for future clinical studies to determine 
the role of INDO promoter variants with responses to cytokine therapy. The result 
from this study could help to explain interindividual variation of the therapeutic 
effectiveness and toxicity of drugs due to altered tryptophan metabolism. 
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Chapter 4 
Present study Methods 
 
4.1 General study plan 
Although some genetic variations in the indoleamine 2,3-dioxygenase (INDO) 
gene have been identified, no systematic study that identifies and describes the 
functional significance of naturally occurring variants has been performed. 
In the present study, we have applied a resequencing strategy to identify 
common sequence variations in the indoleamine 2,3-dioxygenase gene that might 
cause alterations in IDO enzyme expression and/or activity. This work was followed 
by characterization of the functional significance of the variants in vitro. A schematic 
“road map” of our IDO pharmacogenetic studies is illustrated in (Figure 4.1). 
 
Clinical 
scenario
Back to 
the bench
In-Vitro
In-Silico
Resequencing of INDO 
gene:
Aim 1: Coding region
Aim 2: 5’-flanking region 
Bioinformatic 
analysis
Analyze IDO
Activity
mRNA 
Protein 
Back to In-Vivo
(Genotype / Phenotype 
analysis)
Response to Cytokine 
Treatment Varies
 
 
Figure 4.1 The roadmap for the study of indoleamine 2,3-dioxygenase (INDO) gene 
pharmacogentics. The schematic diagram of the experimental plan consists of 
resequencing of coding and 5’-flnking region, in-silico and in-vitro analysis of INDO 
gentic variants. 
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4.2 Specific Aim 1: To identify indoleamine 2,3-dioxygenase genetic polymorphisms 
in the coding region that affect enzyme expression and/or activity and to evaluate the 
mechanisms by which these variants influence activity. 
Several studies have observed variable tryptophan concentrations in cancer 
survivors and found an association with patient’s quality of life 117. A number of 
recent studies showed the correlation between high IDO expression and poor 
prognosis in ovarian, lung and colorectal cancers 34, 118-120. Other studies have also 
reported variable IDO expression in various human cancer tissues 78, 119, 121. Serum 
tryptophan concentration was lower and variable in patients with gynecological 
cancer 120 , suggesting the presence of variable tumormediated IDO activity in these 
patients. Despite a number of studies indicating variable expression of IDO, the 
causes are not fully understood. The main goal of specific aim 1 is to identify and 
evaluate the mechanism by which genetic polymorphisms in the coding region affect 
IDO activity. 
The complete IDO genetic polymorphism study consists of resequencing of 
the coding region, sequence data analysis, in vitro transient expression, IDO activity 
assessment and understand the mechanism of loss of IDO activity. A flow chart 
illustrating the experimental approach is shown in (Figure 4.2). The components of 
the work flow are discussed in detail in each section below.  
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4.2.1 Experimental design 
 
Figure 4.2 Flow chart used in the study of IDO genetic polymorphisms in the INDO 
coding region. 
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4.2.2 Materials and Methods 
 
Table 4.1 Cell lines used in this study. 
 Cell Lines Origin and Characteristics Base line IDO Activity# 
COS-7 
Ls174T 
Green monkey kidney cell 
Human colorectal adenocarcinoma 
Undetectable 
High 
A549 Human lung cancer cell High 
HEK293 
SkBr3 
Human embryonic kidney cell 
Breast cancer 
Undetectable 
High 
# IDO activity is measured based on the formation of kynurenine in the culture media after 
 growing cells for 24 hr ( if not mentioned). 
 
 
Table 4.2 Chemical and drugs used in the study. 
Drug name Manufacturer Catalog # 
Hemin Fluka WA11440 
MG132 Sigma C2211 
Lactosyctin Sigma L7035 
Trypan Blue Stain Lonza 17-642E 
G418 Sigma A1720 
Chloroquine 
Succinylacetone 
Interferon-γ 
L-tryptophan 
3-nitro tyrosine 
4-Dimethylamine-benzaldehyde 
Kynurenine 
D/L-Tryptophan 
DMSO 
Ethanol 
Sigma 
Sigma 
Roche 
Sigma 
Sigma 
ACROS 
Sigma 
Sigma 
Sigma 
Sigma 
C6628 
D1415 
11 040596001 
T8941 
N7389 
100-10-7 
K8625 
T7425 
D2438 
E7023 
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4.2.3 Resequencing/Identification of variants in INDO gene coding region 
To achieve this aim, we resequenced the exons and intron/exon boarders of 
the INDO gene using DNA samples from 48 African American and 48 Caucasian 
subjects obtained from the Coriell DNA Repository (Camden, NJ). These samples 
 (Sample sets HD100 AA and HD100 CA) were diversity panels deposited by the 
NIGMS, National Institute of Health. The samples had been anonymized before 
deposit, and all subjects had provided written informed consent for the use of their 
DNA for research purposes.  
We used the human INDO gene consensus sequence designated as Homo 
sapiens chromosome 8 genomic contig accession number X_17668. Resequencing 
was completed using the high throughput sequencing services of Polymorphic DNA 
Technologies, Inc (www.polymorphicdna.com). Primers used for the sequencing of 
INDO coding region are listed in Table 4.3. 
Table 4.3 Primers used to resequence coding region. BST- Boost, NST-Nested 
Sequence  
description 
Sequence Amplicon size 
(bp)
Exon 1_1  
BST5'- CGGCCACCTGTTTTCATAGT 385
BST3'- TTGGCCAGGTAAGGAATGAG 
NST5'- AGGCCTTTCTGGCTTCCTAT 
NST3'- TTACCTGTGGATTTGGCAGA 
Exon 1_2  
BST5' TGAAACCATTCCAAAAGTGG 399
BST3'- CACCACTCTCCGTATCCATGT 
NST5'- AATTTCTCACTGCCCCTGTGAGATGA 
NST3'- CTCCATTTCTAGGGAGA 
Exon 2-3_1  
BST5'- GGTGGAACACAGAGAGGGTCT 434
BST3'- CCACACATATGCCATGGTGA 
NST5'- TGACAAGACAGAGGCTGGTG 
NST3'- TCCCAGAACTAGACGTGCAA 
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Exon 2-3_2 
BST5'- CATTGCTAAACATCTGCCTG 416
BST3'- GGAGGCCCATGTGTGTTTTA 
NST5'- GCCAGCTTCGAGAAAGAGTT 
NST3'- TCAAGCCAGGGCATATTTTC 
Exon 4  
BST5'- AAGGCCGGAGGATCAC 458
BST3'- GCAGTCCAAGAAACCGTACC 
NST5'- TGGTGGCAGGTGCCTATAAT 
NST3'- CGAGGAACTGAGAGGAACCA 
Exon 5  
BST5'- CCGGCCCTAGTTCTGAGTT 499
BST3'- TCATAGTTCCAAAGCCAGATTTT 
NST5'- CTTGGACAATGGGCCTAAAA 
NST3'- TACAGAGGTTTCAAGTTGGATTT 
Exon 6  
BST5' CTGAAGTGGGCGGATCAC 472
BST3'- GCTTGGAACTCTGGCTTCAC 
NST5'- GTGGTGGGCACCTGTAGTC 
NST3'- CCACATAGAAAGTGGAATGGTTT 
Exon 7  
BST5'- AACAGTTTACTTGTTACGTCAGTAAGC 410
BST3'- TCCTGAGCAGATTTGGCATA 
NST5'- TTCCTGGAAGAGGGTAGGAAA 
NST3'- TCCCCCACTCCAGTACATTC 
Exon 8  
BST5'- TTATGCCAAATCTGCTCAGG 426
BST3'- CTGGTTCACAAGGAACCTGTC 
NST5'- GGCAAGGGGGTATGAAAAA 
NST3'- CCAAATCCCTACTTGCCTGA 
Exon 9  
BST5'-          TGAGTTTAGCTCATTCAGTTTTCA 441
BST3'-          CCTTCCTTCAAAAGGGATTTC 
NST5'-          GCCAAACATTAGCCTTCAAA 
NST3'-          TCAGTGCCTCCAGTTCCTTT 
Exon 9_2  
BST5'- TGCCTTTCTCTCCTGGATTG   458
BST3'- TTACCTTTTGTTGTTTTCCTACAA 
NST5'- CCACCAGCTCACAGGAACTT 
NST3'-          TGCACAGGTATTTTGAGGTCTTT 
Exon 9_3  
BST5'-          GACCCTTCAAAACTGGAAGC 450
BST3'-          CCAGGTTCACGCCATTCT 
NST5'-          AAAGGAACTGGAGGCACTGA 
NST3'-          CCGTGTTAGCCAAGATGGTC 
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For both Boost and Nested PCR the following cycle conditions were used : 
94ºC for 4 min, 94ºC for 0:20 min, 55ºC for 0:25 min, 72ºC for 1:00 min (39 cycles) 
and final 72ºC elongation for 7 min and hold at 6ºC. 
 
4.2.4 Identification of variants in the INDO gene and bioinformatics analysis 
4.2.4.1 Vector NTI Advance  
One of the most useful programs for basic DNA sequence analysis and for 
laboratory maintenance of plasmid constructs is Vector NTI™. Vector NTI Advance 
is the most highly integrated, multifunctional desktop sequence analysis. Vector NTI 
Advance contains a comprehensive set of data analysis and management tools 
implemented across five application modules. All modules share an information-rich 
graphical user interface that makes sequence analysis both simple and intuitive.  
The five modules are listed below: 
Vector NTI™: mapping, analysis, annotation, illustration and management 
ContigExpress™: DNA sequence assembly 
GenomBench™: analysis and annotation of reference genomic DNA sequences 
BioAnnotator™: functional annotation of proteins and DNAs 
AlignX™: multiple sequence alignment of proteins and DNAs  
The sequencing was performed in both directions (using the primers in Table 4.3). 
The sequence information that was collected from the 48 African Americans and 48 
Caucasians was available in a chromatogram format i.e. .ab1 files and .seq files.  
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Contig Express module of Vector NTI Advance was used for variant 
identification. Contig Express is a DNA assembly application for building contigs 
from individual overlapping sequence runs. Once assembled, a contig can be edited, 
with linked chromatograms in full view, and an edit history is maintained allowing 
the option to undo any change made to the contig in the assembly process at any time. 
The input INDO data from the commercial sequencing service was the sequencing 
chromatograms and the summaries excel files. 
Using the Contig Express™ module, a new assembly project was created for 
the combination of DNA sequences of samples of the African American or Caucasian 
population. This was done by adding fragments in the form of .ab1 files for the above 
mentioned populations. The wild type sequence of each exon is used as a reference 
X_17668; this sequence was obtained from ENSEMBL in the form of a text file. 
After selecting sequence files in both directions, their fragmented ends were trimmed 
as it includes noisy data with no accurate peaks. Then all these fragments were 
assembled into one contig to identify variants. The software shows the sequence 
variations in the form of ‘+’ or ‘N’ sign. Some variations may be due to artifacts or 
missing nucleotides. So, all variation marked chromatograms were manually checked 
to verify the true variations. If they are real variations, they are further analyzed to 
determine whether they fall in the intron or exon part of the sequence. To exclude  
PCR induced artifacts, independent amplifications were performed for variants that 
were observed only once or for any amplicon that had an ambiguous chromatogram. 
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Once the variant identification process was completed, a subsequent 
bioinformatics assessment was done for further analysis of the INDO variants. One 
goal of functional genomics is to enhance our ability to predict the functional 
consequence of naturally occurring polymorphisms. It was shown in a recent study 
that the impact of amino acid allelic variants on protein structure/function can be 
reliably predicted via analysis of multiple sequence alignments and protein 3D-
structures 122. The need to obtain functional information for the increasing number of 
new sequences and structures pushed the development of several methods for the 
prediction of functional consequences of variants. Depending on the information 
available for the target protein (example sequence alone, 3D structure, sequence 
homologous and crystal structure), different sets of methods can be used. Although 
these methods are not perfect, they are helpful since it is time consuming and difficult 
to experimentally obtain functional data for the overwhelming stream of new SNPs.  
Bioinformatic methods can help prioritize a SNP for wet lab functional studies; 
for example, it can prioritize a set of candidate SNPs/variants to study, rather than 
blindly trying all SNPs found in the sequence. A combination of both  
experimental and in-silico, approaches can help interpret the functional impact of a 
set of SNPs. To achieve of this goal for the INDO SNPs, we used three different  
complementary bioinfromatic approaches. They are position specific phyelogenetic 
information for multiple sequence alignments CLUSTAL W (1.83), from prediction 
software’s PolyPhen (Polymorphism Phenotyping) and SIFT (Sorting Intolerant From  
Tolerant). The properties for each of the 3 are computed based on amino acid 
characteristics. 
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4.2.4.2 CLUSTAL W (1.83) Multiple Sequence Alignments 
The simultaneous multiple sequence alignments of many nucleotide or amino 
acid sequence is a key tool in sequence comparison. Multiple alignments are used to 
find patterns to characterize homology between sequences. It is now one of the most 
widely used bioinformatics analyses. Conservation was assessed by multiple sequence 
analysis using CLUSTAL W. The input was the INDO sequences from multiple 
species found by FASTA search in the uniport database. These are Dog (XP_532793), 
Mouse (NP_032350), Rat (NP_076463) and Cow (XP_582707). 
 
4.2.4.3 PolyPhen (Polymorphism Phenotyping) 
PolyPhen (Polymorphism Phenotyping) is an automatic tool for prediction of 
the possible impact of an amino acid substitution on the structural and functional 
properties of a protein. PolyPhen (http://www.bork.embl-heidelberg.de/polyphen) 
combines a conservation score with additional properties (example physicochemical 
differences and structural features of the polymorphic variants) in order to predict the  
functional importance of an amino acid alteration 123. This prediction uses empirical 
rules, which are applied to the sequence, phylogenetic, and structural information 
characterizing the substitution.  
 
4.2.4.4 SIFT (Sorting Intolerant From Tolerant) 
SIFT (Sorting Intolerant From Tolerant) is based on the premise that 
important amino acids will be conserved among sequences in a protein family, so 
changes at amino acids conserved in the family should affect protein function. Given 
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a protein sequence, SIFT chooses related proteins, obtains an alignment of these 
proteins with the query, and based on the amino acids appearing at each position in 
the alignment, makes a prediction as to whether a substitution will affect protein 
function. A position in the protein query that is conserved in the alignment will be 
scored by SIFT as intolerant to most changes; a position that is poorly conserved will 
be scored by SIFT as tolerant to most changes 100, 124, 125. Unlike PolyPhen, SIFT 
does not require structural information of the protein.It follow that it can be applied 
to a much larger number of proteins. (http://blocks.fhcrc.org/sift/SIFT.html) 
Even when the structural information is available, we still may be unable to 
accurately predict the functional implication of all alterations in amino acid sequence 
when placed in the complex context of intracellular environment 106.  
The planned approaches for this problem use a range of prediction tools, 
mainly physical and chemical properties of the amino acids, structural properties of 
the encoded protein and evolutionary properties derived from sequence alignments of  
homologous proteins 126.  
 
4.2.5 Reconstruction of vectors by site-directed mutagenesis 
To test the functional significance of the two nonsynonomous SNPs (exon 1-
Ala4Thr and exon 3-Arg77His) and a 9 bp deletion on exon 7, mutations were 
introduced in the pCMV-Sport6 vector (Figure 4.3), which contained the full length 
IDO cDNA (NM 002164.2) in the (clone ID 5208340 purchased from Invitrogen, 
Carlsbad, CA).  
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http://www.invitrogen.com
 
Figure 4.3 Plasmid map of pCMV-Sport6. 
 
Polymerase chain reaction (PCR) based site directed mutagenesis 
QuickChange® II Site-Directed Mutagenesis kit (Stratagene® La Jolla, CA) was used 
for the introduction of INDO variants. This Strategene QuickChange site directed 
mutagenesis kit utilizes a simplified way of introducing variations directly into the  
pCMV-Sport6 expression vector. Variations were introduced separately, using two 
primers containing the desired mutations (Table 4.4). All primers used for the site-
directed mutagenesis were synthesized by Integrated DNA Technologies, Inc.  
(Coralville, IA). The primers, each complimentary to opposite strands of pCMV-
Sport6-IDO, were extended during temperature cycling using high fidelity DNA 
polymerase. Incorporation of the primers generated variant vectors containing 
staggered nicks. Following temperature cycling, the products were treated with a 
restriction enzyme specific for methylated DNA, and parental DNA templates were 
digested causing the selection of variant-containing synthesized DNA (Figure 4.4). 
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The nicked pCMV-Sport6-IDO vectors containing variant IDO were then 
transformed into XL-blue super competent cells by heat shocking. Clones with 
variant plasmids were selectively grown in ampicillin-containing medium, during 
which time the nicks of the variant plasmids were repaired. 
Subsequent subcloning of the variant IDO cDNAs into the eukaryotic 
expression vector pcDNA3 Figure 4.5; Invitrogen (Carlsbad, CA) was performed to 
exclude the risk of having any additional mutation in the vector generated during 
mutagenesis. The variant pCMV-Sport6-IDO construct and the native pcDNA3 
vector were digested at NotI and EcoRI sites. The fragments were separated by size 
on 1% agarose gel and the DNA fragments were purified using a QIAquick Gel 
Extraction Kit Qiagen (Hilden, Germany). Restriction fragments containing IDO 
constructs were subsequently ligated into pcDNA3 using a rapid ligation kit New 
England BioLabs (Ipswich, MA). Transformation into MAX Efficiency®DH5α™  
competent cells from Invitrogen (Carlsbad, CA).was achieved by heat shock. Finally, 
purification of amplified pcDNA3-IDO constructs and verification of variations were 
completed by sequencing the insert (IDO cDNA) in both directions. The schematic 
diagram in (Figure 4.4) illustrates the QuickChange® II Site-Directed Mutagenesis 
system based on polymerase chain reaction. 
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pCMV-SPORT6 Denaturation of dsDNA of pCMV-SPORT6and subsequent annealing of two mutagenic 
IDO primers. 
Incorporation and extension of mutagenic primers
resulting in nicked circular strands. 
Digestion of the methylated, nonmutatedparental DNA
template with Dpnl, leaving the mutated plasmid 
containing nicked circular starnds.   
http://www.stratagene.com
Parental plasmid
Mutagenic primer
Mutated plasmid
Transformation and subsequent reparation of nicks
in E.Coli XL1-Blue and further subcloing of IDO
into pcDNA3 mammalian expression vector.
 
Figure 4.4 Overview of the QuickChange® site-directed mutagenesis method 
modified from technical manual provided by Stratagene. 
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Figure 4.5 A plasmid map of pcDNA3.  
Table 4.4 Primers used for the site-directed mutagenesis.  
Sequence 
description 
Sequence 
Ala4 to Thr  
Forward: GCAGACTACAAGAATGGCACACACTATGGAAAACTCCTGG 
Reverse: CCAGGAGTTTTCCATAGTGTGTGCCATTCTTGTAGTCTGC 
Arg77 to His  
Forward: CTCACAGACCACAAGTCACAGCACCTTGCACGTCTAGTTCTG 
Reverse: CAGAACTAGACGTGCAAGGTGCTGTGACTTGTGGTCTGTGAG 
#Arg77 to Lys  
Forward: CTCACAGACCACAAGTCACAGAAGCCTTGCACGTCTAGTTCTG 
Reverse: CAGAACTAGACGTGCAAGGTGCTGTGACTTGTGGTCTGTGAG 
Ala Leu Leu Glu 
to Asp 
 
Forward: GGACACTTTGCTAAAGGCAATAGCTTCTTG 
Reverse: CCAAGCAAGAAGCTATTGCCTTTAGCAAAGT 
# The Arg77Lys variant was not identified in the samples we sequenced. We used it as 
a control for the Arg77His variant. 
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C-terminal hemagglutinin (HA)-tagged wild-type and variant IDO constructs 
were also created using the pcDNA3 construct. The wild-type and variant cDNAs 
were PCR amplified from the plasmids that are described above. To facilitate cloning, 
NotI and EcoRI restriction sites were incorporated into the N- and C-terminal ends of 
the cDNAs. The HA-tag was also incorporated into the C-terminal end, immediately 
before the stop codon. The primers used for HA-tag subcloning are listed in Table 4.5. 
All mutations were verified by DNA sequencing after subcloning.  
 
Table 4.5 Primers used to create the HA-tag construct. 
Sequence Description                                    Sequence 
      Forward:   CCTTTCGAATTCTTAAGCGTAGTCTGGGACGTCGTATG   
                        GGTAACCTTCCTTCAAAA 
 
      Reverse:     CCTTTCTTCGGCCGCAGACACTGAGG 
The amplicon size is 1.5Kb 
 
 
4.2.6 Plasmid DNA quantification with the Agilent 2100 Bioanalyzer 
 
Several techniques have been used in the quantitive analysis of DNA/RNA. 
The most common technique is to determine the absorbance at 260 nm (A260) with a 
UV-spectrophotometer. This detection method has long been the gold standard in 
nucleic acid quantification, largely due to the ease of sample preparation, requiring no 
additional mixing of reagents. One major disadvantage to using UV analysis is the 
impact of sample contaminants such as bacterial genomic DNA during plasmid DNA 
extraction, which also absorb at 260 nm, thereby giving potentially false 
quantification readings. An important advantage of the Agilent 2100 Bioanalyzer  
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DNA 7500 LabChip® kit (Agilent Technologies, Palo Alto, CA) is the ability to 
accurately determine sample concentrations while checking integrity and purity of the 
sample. For analysis with the Agilent 2100 Bioanalyzer, one μl of each sample was 
loaded into a well of a chip prepared according to protocol supplied with the DNA 
7500 LabChip kit. Plasmids were digested with restriction enzyme before loading into 
Agilent. This is because Agilent did not quantify circular plasmid DNA. Briefly, 9 μl 
gel-dye matrix was loaded into the chip in one well and the chips were pressurized for 
30 seconds. Two additional wells were filled with geldye matrix and the remaining 
wells were loaded with 5 μl each of molecular weight marker. One microliter of DNA 
ladder was loaded into a ladder well and 1 μl of sample was loaded into each sample 
well. The chip was vortexed and placed into the Agilent 2100 Bioanalyzer. DNA 
7500 assay was run, which applies a current sequentially to each sample to separate 
products. DNA is detected by fluorescence of the intercalating dye in the gel-dye 
matrix. The concentration of DNA in each sample was calculated from the area under 
the curve for each sample product and a size correction was made since an 
intercalating dye was used to detect DNA (Figure 5.9). 
 
4.2.7 In vitro expression of IDO  
4.2.7.1 Mammalian cell line expression (COS-7 and HEK293) 
A number of mammalian cells were screened for transient expression of IDO 
(Table 4.1). Most of the cell lines tested had high IDO baseline expression and 
activity, which makes them unsuitable to use for transient expression. In order to  
study the effects of variants on the enzymatic function of IDO, Green monkey kidney 
cells (COS-7) and Human embryonic kidney cells (HEK293) were used for transient 
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expression analysis. These cell lines were chosen for two main reasons. Primarily, 
neither cell line has detectable base line IDO activity. The second reason was that 
they are mammalian cell lines that have the post-translational machinery that is 
important for process and folding of newly translated proteins. This could be 
important to assume that the protein is processed correctly and thereby makes it 
biologically active.  
COS-7 cells were purchased from American Type Culture Collection ATCC  
(Rockville, MD), and Human embryonic kidney (HEK293) cells were obtained from 
Dr. Theodore Cummin’s lab, Department of Pharmacology and Toxicology (IUSOM). 
All cell lines were cultured according to the ATCC’s guidelines and all cell lines 
tested negative for mycoplasma.  
 Cells were grown in a humidified atmosphere containing 5% CO2 at 37°C in 
DMEM (Dulbecco's modified Eagle's medium BioFluids International, (Rockville, 
MD) containing a high glucose concentration (4.5 g/l at 25 mM) media was 
supplemented with 50 units/ml penicillin, 50 μg/ml streptomycin Sigma-Aldrich (St. 
Louis, MO) and 10% (v/v) fetal bovine serum. All cells were maintained in T-75 
flasks and passed every 3-4 days when reached in 80-90% monolayer confluence. 
Cells from the same passage used in respective experiment. Harvesting was achieved 
by trypsinization, and subsequently cells were washed re-suspended in medium 
depending on the use. For expression purpose, cells were seeded in different sized  
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cell culture plates and flasks based on the experiment (Table 4.6). Immediately before 
transfection, the medium was removed and replaced with fresh medium without 
serum. 
Table 4.6 Transfection protocol.  
#Number of 
cells 
Culture 
Plate/Flask 
@Plasmid 
DNA 
*Lipofectamine™
LTX 
*PLUS™ 
Reagent 
1 x 105 12-well 0.5 1 1 
2 x 105 6-well 1 2 2 
2.5 x 106 T25 10 40 40 
7.5 x 106 T75 30 120 120 
Different tissue culture format, vary the amount of reagent, DNA, cells used in 
proportion to the relative surface area of the culture plate or flask, as shown in the 
table (amounts given for the plate is per well). 
# Number of cells plated 24 hr before transfection unless it is mentioned. 
 @Plasmid DNA is in μg, all plasmids are diluted to 0.5μg/μl. The amount of plasmid 
used for transfection is based on the table unless it is mentioned. 
 *Transfection reagent both Lipofectamine™ and PLUS™ reagent are in μl. 
 
COS-7 cells were transfected with the wild type and variant IDO-pcDNA3 
expression constructs using COSFectin (BioRad). Briefly, 2 x 105 cells were plated in 
6-well plates for 24 hr before transfection and 0.5 μg of IDO expressing constructs 
were mixed with FBS free DMEM to the final volume to 1ml and mixed with 6 μl of 
COSfectin and incubate at RT for 20 min. The entire amount was added into the well 
drop wise. At 24 hr post transfection, media and cells were harvested and IDO 
activity analyzed using HPLC. 
Lipofectamine™ LTX, Plus™ reagent (Invitrogen Carlsbad, CA) was used for 
the transfection of HEK293 cells according to Table 4.6. An 'empty' pcDNA3 vector  
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(i.e. one that does not contain cDNA) was used as a control to correct for possible 
endogenous IDO enzyme activity in the transfected cells. The plasmid DNA 
concentration was determined by Agilent 2100 Bioanalyzer lab-on-a-chip (Agilent 
Technologies, Palo Alto, CA). All transfections were performed in triplicate on three 
different days and a vector which expresses Renilla luciferase gene was used as a 
transfection control. This was done to confirm equal transfection efficiency allowing 
comparison between trasnfected cells.  
Samples of culture medium (∼1ml) were collected after 48 hr of transfection 
in 1.5 ml micro centrifuge tubes. For plasmid dose dependent experiments, 0.1, 0.5 
and 1.5 μg of plasmid DNA from respective constructs used. For the time course 
experiment culture medium was collected at different time points (12, 24, 48 and 72 
hr) from cells transfected with 0.5 μg respective plasmids. Cells were harvested for 
RNA and protein analysis and were kept at -80ºC; culture media was kept frozen at -
20ºC for measurement of tryptophan and kynurenine concentrations using HPLC in 
most of the studies unless specified otherwise.  
 
4.2.7.2 In vitro transcription and translation of IDO using rabbit reticulocyte 
lysate (TNT-RRL). 
 Transcription and translation of wild type and variant (Ala4Thr, Arg77His, 9bp 
deletion and Arg77Lys) IDO constructs were performed using TNT® couple RRL  
system Promega (Madison, WI) with constructs that had been subcloned into 
pcDNA3. Specifically, 25 μl of T7 buffer, 1 μl of T7 polymerase and, 1 μl of RNasin,  
 42
reagents were included in the Promega (Madison, WI) kit. One μg of pcDNA3 
expression construct DNA was added to the mixture; the reaction volume was 
increased to 50 μl with nuclease-free water and the mixture was incubated at 30ºC for 
90 min.  
 
Figure 4.6 A schematic diagram of the Transcription and Translation linked in Rabbit 
Reticulocyte Lysate system [TNT-RRL] assay. 
 
 
4.2.7.3 Assay of IDO activity in transient expression systems. 
To functionally characterize variant IDO enzymes, the degree of impaired 
enzyme activity was assayed after transiently expressing it in COS-7 and HEK293 
cells. The activity was correlated with the catalytic activity of the wild type IDO. 
Conversion of the substrate (tryptophan) to metabolite (kynurenine) was achieved by 
incubation of the substrate for 48 hr. The degree of substrate conversion of the variant 
was compared with the wild type using substrate concentration of 80 μM in the 
culture medium. Background activity, i.e. activity found after transfection with empty 
vector, was below the detection limit. The natural diffusion/transport of substrate and  
metabolites from the cells to the surrounding medium allowed measurement of both 
substrate and metabolites in the culture medium.  
 43
4.2.7.4 IDO activity measurement in the culture media using HPLC 
Using a published HPLC assay for IDO enzymatic activity measurement 127 as 
a starting point, we optimized and validated a sensitive HPLC assay with UV and 
florescence detection that allowed effective chromatographic separation and 
quantification of tryptophan and its metabolite kynurenine in culture medium. Briefly, 
at the time of analysis, samples were thawed on ice, vortexed, and 200 μl of the 
conditioned media were transferred to a new micro centrifuge tube containing 50 μl 
of 3-nitro-tyrosine (3-NT) as the internal standard. Fifty μl of 30% trichloroacetic 
acid (TCA) was then added to each tube to precipitate out the proteins and the tubes 
were vortexed immediately. The samples were spun in a microcentrifuge at 12,000g 
for 5 min and 200 μl of supernatant was transferred to 8×40 mm amber glass tubes for 
HPLC analysis. All samples were run in triplicate. The two chromatographs (Figure 
4.7) show the typical peaks of tryptophan and kynurenine.  
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Figure 4.7 Representative chromatograms showing the separation of tryptophan and 
kynurenine by HPLC. Cultured medium from the COS-7 cell line transiently 
transfected with wild type IDO cDNA was collected after 48 hr, extracted with 
trichloroacetic acid and the supernatant was loaded on an HPLC. X axis is time in 
minutes; Y axis is millivolt signal from the detectors, ultraviolet (right) 360nm, 
fluorescence (left) excitation =285nm, emmission=365nm. Int Std = internal standard 
(3-nitro-tyrosine). 
 
An HPLC with UV and fluorescence detectors connected in tandem was 
developed for the quantification of tryptophan and kynurenine. The HPLC system 
consisted of a Waters (Milford, MA) model 515 pump, model 717 auto sampler, 
model 490 programmable absorbance UV detector and Hewlett Packard 1046A 
programmable fluorescence detector. The separation system consisted of a Zorbax 
SB-C18 column (150 x 4.6 mm, 3.5 μm particle size; Phenomenex, Torrance, CA), a 
Luna C18 Guard column (30 x 4.6 mm, 5 μm; Phenomenex), with a mobile phase 
composed of 97%, 15 mM KH2PO4 (pH=5.5) and 2.7% acetonitrile (flow rate, 0.8 
ml/min). The column elute was monitored by fluorescence detection at 360 nm for 
tryptophan and by UV detection for kynurenine at 285 nm. Chromatograms look  
similar for analyses from cultured media as well as from serum. The values were 
referred to a standard curve with defined kynurenine (0, 0.16, 0.312, 0.625, 1.25, 2.5, 
5, 10, 20 μM) and tryptophan (0, 1.6, 3.12, 6.25, 12.5, 25, 50,100, 200 μM)  
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concentrations. The limits of quantification for tryptophan and kynurenine are 
approximately 1.6 μM and 0.16 μM, respectively. Decreasing the mobile phase pH 
from 6.5 to 5.5 accelerates the elution and sharpens the tryptophan and kynurenine 
peaks. The retention times of tryptophan and kynurenine were stable over the course 
of time on a single column.  
 
4.2.7.5 IDO activity measurement using a plate reader 
The second method used for the measurement of IDO activity is a colorimetric 
based assay. This procedure was modified from previous report by 128, 129. In the 100 
μl of conditioned medium, 25 μl of 30% (w/v) trichloroacetic acid (TCA) was added 
to precipitate residual cells and proteins in the medium. Then 100 μl Ehrlich reagent 
(p-dimethylaminobenzaldehyde in acetic acid) was add into the TCA treated 
conditioned medium and incubated for 10 minutes at room temperature in a microtiter 
plate. The absorbance at 480 nm for the yellow color derived from kynurenine was 
determined using Synergy2 micro plate reader BioTek (Winooski, VT). The limit of 
quantification for kynurenine is approximately 3.1 μM and limit of detection is 
approximately 1.6 μM. The values were referred to a standard curve with defined 
kynurenine (0, 1.6, 3.12, 6.25, 12.5, 25, 50 100 μM) concentrations. All assays were 
conducted in triplicate. The Ehrlich method used to measure kynurenine is simple,  
robust and it does not interfere with tryptophan. For these reasons, many groups use 
this procedure to quantify kynurenine 129, 130. However, a limitation of the Ehrlich 
method is that it can interact with downstream kynurenine metabolites and  
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overestimate kynurenine formation 131. To avoid this overestimation, we have double 
tested samples with unexpected high kynurenine formation using HPLC. 
 
4.2.7.6 RNA extraction and real time PCR assay 
Total RNA was isolated from the cell cultures after treatment using RNeasy 
mini-kits, according to the manufacturer’s protocol (Qiagen, Inc., Santa Clarita, CA). 
Initially, endpoint RT-PCR analysis was performed to determine if the wild type and 
the variant cDNAs were expressed in both COS-7 and HEK293 cells. In later 
experiments, the assay was converted to a real-time quantification PCR assay as 
described below. Cells were harvested after 48 hr and total RNA was extracted using 
RNeasy kit (Qiagen, Inc., Santa Clarita, CA), following the manufacturer’s protocol. 
Following the extraction of total RNA, the samples were treated with DNase I (DNA-
free™; Ambion, Austin, TX). Total RNA concentrations were measured using 
RNA6000 Nano LabChip kit from Agilent Bioanalyzer lab-on-a-chip (Agilent 
Technologies, Palo Alto, CA). The RNA quality was checked based using the ratio of 
28S/18S ribosomal RNA. Reverse transcription (RT) was performed on 1 μg of RNA 
using Reverse Transcription kit (Promega, Madison, WI). 
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Table 4.7 Primers used for the RT-PCR. 
Sequence 
description 
Sequence Amplicon size (bp) 
IDO-Forward: ACTACAAGAATGGCACACGC 406 
IDO-Reverse: TTGCCAAGACACAGTCTAC  
GAPDH-Forward: GAA GGT GAA GGT CGG AGT 227 
GAPDH-Reverse: GAA GAT GGT GAT GGG ATT TC  
All primers were purchased from Integrated DNA Technologies, Inc. (Coralville, IA). 
The specific sequences of primers were designed using Primer 3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) 
 
Quantitative real time RT-PCR analysis using SYBR Green was performed to 
assess the mRNA level in HEK293 cells transiently transfected with the wild type and 
variant IDO constructs. Briefly, the reaction volume was set at 25 μl with the 
following composition. Primers were diluted to a 20 μM stock solution and used 0.25 
μl each (to a final concentration 200 nM). SYBR green was used to quantify the PCR 
products. Fluorescein was included for the iCycler well-factor correction. The 
samples were amplified using the Platinum Supermix UDG (2X) (Invitrogen, 
Carlsbad, CA). Two μl of cDNA were used in the reaction and the volume was made 
up by water to a final volume of 25 μl. Samples were amplified using the following 
conditions. Samples were incubated at 50ºC for 2 minutes followed by 30 cycles of 
amplification using the following program: denaturation at 95ºC for 30 sec, annealing 
at 54ºC for 1 minute and extension of PCR product at 72ºC for 1 minute and final 
extension at 72ºC for 10 minutes. The 2-ΔΔCt method was used to calculate  
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relative changes in gene expression determined from real-time quantitative PCR 
experiments 132. GAPDH was selected as the housekeeping gene for normalization. 
Basically, each gene was running along with GAPDH and difference between 
threshold cycle (CT) was designated as ΔCT. Then the difference between their 
respective controls was calculated and designated as ΔΔCT. 
 
4.2.7.7 Determination of total protein content  
HEK293 cells were harvested and washed twice with PBS and subsequently 
mixed with cell lysis buffer and cell disruption was performed by sonication. Briefly, 
pellets from HEK293 cells trasfected with respective IDO plasmids were washed and 
resuspended in 500 μl lysis buffer. The suspension material was sonicated by a multi-
step scheme. Each step consisted of three cycles of disruption using a microtip with 
40W Ultrasonic homogenizer model 150VT from Biologics, Inc (Manassas, VA) for 
30 sec on ice bath and incubation on ice for 5 min, followed by centrifugation at 12 
000 g and at 4ºC for 5 min to separate the soluble fraction from the pellet. 
Protein concentration was measured using a protein assay based on the BCA 
method (Pierce, Rockford, IL). Supernatants from sonicated cells were incubated with 
protein assay buffer using a range of concentrations of bovine serum albumin as a 
protein standard. Samples were measured thereafter on a plate reader and the protein 
concentration was estimated using the reference values from the protein standards. 
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4.2.7.8 Western blot analysis 
The indoleamine 2,3-dioxygenase protein concentrations in the transfected 
HEK293 cells were determined by Western blot. Total protein concentrations were 
determined using the BCA method (Pierce, Rockford, IL). Briefly, 25-100 µg of  
total protein from each samples were loaded and separated on a 4-20% SDS-
polyacrylamide gel Invitrogen, (Carlsbad, CA). Electrophoresis was performed for 1 
hr and 30 min at 125 V, and proteins were transferred to Polyvinylidene fluoride 
(PVDF) membranes overnight at 4ºC at 35 V. The membranes were then blocked 
overnight with 5% milk powder in TBST (Tris-HCl (25 mM; pH 7.5), KCl (3 mM), 
NaCl (140 mM) Tween-20 (0.05%). The following day, the membrane was 
incubated with an anti-IDO primary antibody (final concentration 1 μg/ml) in 5% 
milk powder in TBST. We used a mouse anti-human monoclonal antibody directed 
against human IDO (hIDO) amino acids 78-184 US Biological, (Swampscott, MA; 
Catalog # I7545-01). Following the primary incubation, the membranes were washed 
three times. The secondary antibody was a goat anti-mouse horseradish peroxidase 
(Pierce, Rockford, IL) diluted 1:10,000 in 5% milk powder in TBST. The secondary 
antibody was incubated for 2 hr and then washed three times in TBST. The bound 
antibody was detected by enhanced chemiluminescence performed with the ECL™ 
Western Blotting Analysis Kit Pierce, (Rockford, IL). For the HA-tag western blots, 
the same procedure was used with the following modifications: The primary 
antibody (anti-HA, Upstate, Temecula, CA; catalog #05-904; final concentration 2 
μg/ml) was incubated in phosphate buffered saline Tween-20 (0.05%) in 5% milk 
powder. β-actin was used as a loading control. Membrane was stripped using 
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Restore™ Western Blot Stripping Solution Pierce, (Rockford, IL) according to 
manufacturer's specifications. Membranes were blocked and probed with anti-beta 
actin antibody (1:1000, A5441; Sigma) for 3 hours in blocking solution, and then 
membranes were washed three times. The secondary antibody was a goat anti-mouse 
horseradish peroxidase (Pierce, Rockford, IL) diluted 1:10,000 in 5% milk powder in 
TBST. The bound antibody was detected as described above. 
 
4.2.7.9 Quantitative Western blotting and IDO activity 
To evaluate whether variation in enzymatic activity resulted from differences 
in enzyme expression, rather than reduced function of the variants, wild type and 
variant proteins were analyzed by Western blotting. Since enzyme activities were 
expressed as pmol/mg/hr, it was crucial to accurately assess the total amount IDO 
protein expressed. A comparison of enzyme activities could be done only after 
correction for protein content was completed.  
HEK293 cells were seeded in a T225 flask and transfected with wild type, 
Ala4Thr and Arg77His variants for 48 hr using the pcDNA3-HA IDO constructs 
according to the transfection protocol in Table 4.6. Cell lysates from several T225 
flasks for each construct were pooled together. Because cell harvesting by ordinary 
trypsinization may lead to degradation of proteins, mammalian protein extraction  
reagent (Pierce, Rockford, IL; Catalog # 78501) was directly applied on the cell 
culture plate. Total protein concentration was measured as described above using 
BCA. To obtain the equivalent amounts of immunoreactive IDO protein, we 
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gradually reduced the amount of total protein loaded on the gel for the wild type and 
Ala4Thr variant, but at the same time by increasing for the Arg77His and Arg77Lys  
until we got comparable bands for all IDO constructs. The same western blot 
procedure was used as described above paragraph. 
 
4.2.7.10 Kinetic parameter determination 
Prior to enzymatic assays, IDO proteins were expressed in HEK293 cell 
systems and cell lysates were prepared as described above. For a more accurate 
assessment of the quantitative differences in IDO activity for variant proteins, 
HEK293 cells transiently expressing different IDO constructs were characterized for 
IDO protein expression by Western blot analysis. To establish the functional effect of 
nonsynonymous polymorphisms of Ala4Thr, Arg77His and Arg77Lys on tryptophan 
metabolism, we conducted enzymatic assays with IDO proteins obtained from HEK 
293 cells over expressing each variant protein. First the enzymatic assay was done 
with the wild type IDO containing 0, 50, 100 and 200 mg total proteins in 200 μL. 
The incubation medium contained the following: 0.8 mmol/l L-tryptophan, 40 mmol/l 
ascorbic acid, 20 μmol/l methylene blue, 200 U/ml catalase, and 100 mmol/l 
potassium phosphate buffer (pH 6.5) in 200 μL. Both the cell lysate and the reaction 
buffer were pre-incubated at 37ºC for 5 min. Reactions were started by adding 200 μL 
of reaction buffer into the tube with the cell lysates and incubated at 37ºC for 1hr.  
The reaction was terminated by adding 100 μL of 30% (w/v) trichloroacetic acid and 
incubated at 50ºC for 30 min to hydrolyse N-formylkynurenineurenine produced by 
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indoleamine 2,3-dioxygenase to kynurenine. The reaction mixture was then 
centrifuged for 10 min at 12000 g to remove sediment. Formation of kynurenine was  
measured as described above using the plate reader assay. Relative IDO activities are 
expressed as formation of kynurenine in pmol/mg/hr.  
For kinetic analysis of the different IDO constructs, data derived from 
determination of enzyme activity at each of the six substrate concentrations were used 
(6.25, 12.5, 25, 50,100 and 200 μM). Determination of the kinetic variables was done 
using simple ligand binding one site saturation Sigmaplot 8.0 (Systat Software, Point 
Richmond, CA). Kinetic constants (Km and Vmax) were estimated by nonlinear 
regression analysis using Sigma Plot. Formation rates (V) of metabolites versus 
substrate concentrations (S) were fit to a simple Michaelis - Menten Equation 
 (V = Vmax · S/ (Km + S)). Based on this equation, the intrinsic clearance  
 CLint = Vmax/Km estimation values were calculated.  
 
4.2.7.11 Protein degradation inhibitors and IDO activity 
HEK293 cells were seeded in a 6-well plate and transfected with wild type or 
variant IDO for 48 hr using the pcDNA3 IDO constructs as described above in Table 
3.6. To assess the effect of proteasomal inhibition on IDO activity cells were treated  
with hemin, MG132, or lactocystin for 24 hr after transfection. Each drug was used at 
2.5, 5 and 15μM. Media was harvested after 24 hr drug exposure and formation of 
kynurenine measured using HPLC.  
The effect of the lysosmal pathway inhibitor, chloroquine, was tested in 
HEK293 cells transiently transfected with Arg77His variant. Cells were treated with 5, 
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10 and 20 μM chloroquine for 24 hr and the formation of kynurenine analyzed in the 
culture media. Cells harvested from each well and IDO expression assessed by 
Western blot. 
 
4.2.7.12 Alteration in cellular heme concentrations 
IDO must have heme incorporated into it to function. Heme is one important 
member of the porphyrin family. It is synthesized in both mitochondria and 
cytoplasm, and is a key prosthetic group for various essential proteins such as 
cytochromes, catalases and indoleamine 2,3-dioxygenase. Since alteration in the 
heme component of IDO could be a mechanism by which the genetic variants affect 
the enzymes function, we evaluated heme concentrations and manipulated them in a 
transient expression system. 
HEK293 cells were treated with succinylacetone for 12 hr before transfection 
with wild type and variant IDO plasmids. Heme concentrations in the cell lysate were 
measured using QuantiChrom™ Heme Assay kit (Bioassay systems, Hayward, CA). 
This assay is based on an aqueous alkaline solution method, in which the heme is 
converted into a uniform colored form. The intensity of color, measured at 400 nm, is  
directly proportional to the heme concentration in the sample. The linear detection 
range of this assay is 0.6-125 μM heme. Fifty μl of sample mixed with 200 μl of  
reagent and incubated at room temperature for 5 minutes. After 5 minutes incubation 
optical density was read using Synergy2 microplate reader (BioTek, Winooski, VT). 
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Heme concentrations were calculated based on the formula below.  
= ODsample - ODblank / ODcalibrator - ODblank X 62.5 X n (μM) 
Water used as a ODBlank , OD Sample, ODCalibrator, n is a dilution factor. 
 
Cell viability was assayed using CellTiter 96® AQueous One Solution Reagent 
(Promega, Madison, WI). Twenty μl of one solution reagent were added to each well 
of the 96-well plate containing HEK293 cells transfected with wildtype and variant 
IDO construct and subsequently treated with hemin in 100 μl of culture medium. 
Plates were incubated for 2 hr at 37ºC in a humidified, 5% CO2 atmosphere and 
absorbance was recorded at 490 nm using a 96-well plate reader (BioTek, Winooski, 
VT). The absorbance values at 490 nm were corrected by subtracting the average 
absorbance from the vehicle treated wells. 
The proteasomal, lysosome and heme synthesis inhibitors effect on cell 
viability were tested using Trypan Blue Stain (Lonza Inc., Allendale, NJ). Viable 
cells, excluding trypan blue, were counted in a hemocytometer at the indicated drug 
concentrations and compared with the vehicle treated cells. Cells were harvested after 
24 hr drug exposure and 100 μL cell suspension was mixed with 100 μL of 0.4%  
trypan blue and incubated for 5 minutes at room temperature. Ten μl of stained cells 
placed in a hemocytometer and count the number of viable (unstained) and dead 
(stained) cells.  
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4.2.8 Statistical analysis 
Data are expressed as mean ± SD, and statistical analyses were performed with the 
SPSS statistical program. One-way analysis of variance with the Dunett t-test was 
used to evaluate the difference between wild type and variants. A p-value less than 
0.05 was considered significant. 
 
4.3 Specific Aim 2: To identify genetic variants in the IDO promoter and to assess 
their functional significance. 
We hypothesize that genetic variations in the IDO promoter cause functional 
changes in IDO expression and activity.  
The long term goal for this research is to have a better understanding of 
potentially damaging variants; this would enable physicians to make reliable 
assessments of individuals’ risks of particular disease susceptibility, and help explain 
interindividual variation of the therapeutic effectiveness and toxicity of drugs caused 
by altered tryptophan metabolism.  
Endogenous and exogenous cytokines play an important role in regulating 
IDO expression. The molecular mechanisms responsible for IFN-γ mediated IDO 
inductions have been characterized in human fibroblasts 133. The region upstream of  
the IDO transcriptional start site contains numerous regulatory elements, several of 
which are characterized as being important in IFN-γ responsiveness 134, 135. There are 
two distantly separated IFN-stimulated response elements (ISRE-1 and ISRE-2). 
There are three gamma activation sequences (GAS-1, GAS-2 and GAS-3) with in the 
1.3 kb region upstream of the transcription start site 136-138. Studies using a reporter 
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construct have been effective in characterizing the regulatory region important for the 
response of IFN-γ. These response elements have shown to be essential to the 
transcription of IDO in response to IFN-γ 138. Although IDO is primarily an IFN-γ 
induced gene, other inflammatory mediators also mediate the induction of IDO 137, 138. 
There is variability in IFN-γ mediated expression of IDO in different tumor cell lines 
[Cao unpublished data]. However, the molecular mechanisms contributing to this 
variability are unknown. Little is known about the genetic variants of the IDO 
promoter and the functional significance of these variants. It is likely that genetic 
polymorphisms in the IDO promoter region alter IDO expression.  
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4.3.1 Experimental design 
Our studies focused on genetic polymorphisms in the INDO 5’-flanking 
region consisted of SNP identification and functional studies. The SNP identification 
studies involved gene resequencing and bioinformatic analysis of the sequence data. 
The functional studies involved in vitro, transient transfections; these were used to 
evaluate the promoter activity. A flow chart describing the experimental approach is 
shown in Figure 4.8.  
 
 
 
Figure 4.8 Experiment flow chart used in the study of IDO genetic polymorphism in 
the 5’-flanking region. 
 
 
 
 
 58
4.3.2 Resequencing/Identification of variants in the 5’-flanking region of INDO 
gene  
In addition to the core promoter sequence, the INDO 5’-flanking region 
contains several other functional transcription factor binding sites. In fact, functional 
elements -1246/-1018 and -150/-10 control activity of the human IDO promoter; this 
is particularly important for the interferon gamma regulation 139, 140. Therefore, we 
engaged in a systematic analysis of these two particular portions of the INDO gene 
promoter. 
Two PCR primer pairs, encompassing 400 bp were designed to resequence a 
portion of the 5’-flanking region. These were used to assess the nature and extent of  
nucleotide variation in what is believed to be the functionally important parts of 
thehuman INDO gene promoter. The primer sets used for each target were designed to 
include sequences corresponding to the known functional transcription factor binding 
sites (Table 4.7). The portion of the 5’-flanking region covered by the sequencing 
primers are highlighted in Figure 5.22.  
We used the same DNA sample set as used in the specific aim 1. This 
consisted of 48 African-American and 48 Caucasian subjects from the Coriell DNA 
Repository (Camden, NJ.). Sample Sets HD100CAU and HD100AA were used. The 
resequencing and SNP identification was done using commercial services of 
Polymorphic DNA, Inc. DNA was sequenced in both the forward and reverse 
directions. Each polymorphic site was verified by examining the chromatograms 
using the Vector NTI AdvanceTM software and the excel spread sheet from received 
from polymorphic DNA. 
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Table 4.8 Primers used to sequence the 5’-flanking region of INDO gene. 
Sequence  
description 
Sequence Amplicon size (bp)
Ref. sequence 1   
#BST5'- TTTCTCCTTTTGATCATCTAGAGGA 461 
BST3'- ACACAACCTGTGTTATACTCAACTA  
*NST5'- GCAACTTGGTTTCTTCTTTAGC  
NST3'- TCAATGGCTCTGAAGTAGGAAA  
   
Ref. sequence 2   
BST5'- TAAAACGTTGTTCCATGTCTTCACT 484 
BST3'- TTCCTCTAGATGATCAAAAGGAGA  
NST5'- TGACTCACCCATAAAAACTTCAAGT  
NST3'- AGAGAAATAGTTCGTGTGAGTAAAC  
For both #Boost and *Nested PCR the following cycle conditions were used : 94ºC for 
4 min, 94ºC for 0:20 min, 54ºC for 0:25 min, 72ºC for 1:00 min (39 cycles) and final 
72ºC elongation for 7 min and hold at 6ºC. 
 
 
4.3.3 Bioinformatics analysis: Transcription factor binding site search 
The analysis of regulatory regions in the genome sequence is mainly based on 
the identification of potential transcription binding sites (TFBS). Vector NTI Advance 
was used to analyze the SNPs identified by the resequencing chromatograms. 
The genomic sequence of 1.3 kb upstream of the IDO translation site was 
analyzed for putative transcription factor binding site using TRANSFAC and 
JASPAR. The Sequence was screened at high levels of stringency for human 
transcription factors with a transcription factor score of 95% (the default is 80%). For 
the analyses based upon cross-species conservation, we aligned each human promoter 
sequence with 10 kb of mouse sequence that is immediately 5' to the relevant 
orthologous reference mRNA sequence in GenBank. We used the ‘all vertebrate’ 
transcription factor setting combined with the default settings for conservation and 
transcription factor scores.  
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4.3.3.1 TRANSFAC 
Computational analysis of regulatory properties of DNA is most often based 
on the use of matrix models describing binding preferences of transcription factors, or 
other DNA patterns 141. 
In order to elucidate transcription factor binding sites (TFBS) within the 
INDO promoter, we used TRANSFAC. This is a database on eukaryotic cis-acting 
regulatory DNA elements and trans-acting factors. TRANSFAC employs a simple 
correlation calculation with binding site profile matrices to derive results. Data within  
TRANSFAC have been generally extracted from the original literature. We submitted 
the 1.3 kb IDO promoter sequence and selected a high-scoring threshold of 95.0 142. 
 
4.3.3.2 JASPAR 
In addition to TRANSFAC, we also queried TFBSs using JASPAR. It is an 
open-access annotated database of experimentally derived TFBS profiles. We used 
the same promoter sequence and a threshold value of 95.0. This database (JASPAR) 
is the most comprehensive open-access database holding such models 143, 144. 
 
4.3.4 Isolation of 1.3 kb of 5’-flanking region of INDO gene  
Primers were designed using Primer 3 (http://frodo.wi.mit.edu). The 3' primer 
for target promoter was designed to include sequence corresponding to the 
transcription start site in the amplicon. It did not include any coding sequence in order 
to avoid changing the open reading frame of the reporter gene or making a target-
reporter fusion protein. We included no more than 100 bp of 5'-fanking region and 
avoided inclusion of any untranslated ATG sequences. DNA from individuals with 
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specific promoter variants has amplified using Expand High Fidelity DNA 
polymerase (Roche, Indianapolis, IN) to minimize mis-incorporation of nucleotides. 
According to the following PCR condition 1.3 kb of 5’-flanking region of INDO gene 
amplified: denaturation at 95ºC for 30 sec, annealing at 54ºC for 1 minute and 
extension of PCR product at 72ºC for 1 minute and final extension at 72ºC for 10 
minutes.  
 
To clone the insert into a luciferase reporter plasmid, the PCR products were 
digested at NheI and XhoI sites (Table 4.8) and the fragments were separated by size 
on 1% agarose gel, DNA fragment were purified using a QIAquick Gel Extraction Kit 
(Qiagen; Hilden, Germany). Restriction fragments containing 1.3 kb of 5’-flanking 
region of IDO promoter were subsequently ligated into pGL4.10 (Figure 4.9) using a 
rapid ligation kit (New England BioLabs; Ipswich, MA). Transformation into MAX 
Efficiency®DH5α™ competent cells (Invitrogen; Carlsbad, CA) was achieved by heat 
shock. Finally, purification of amplified constructs and verification of variations was 
completed by sequencing the insert (INDO 5’-flanking region in pGL4.10 vectors) in 
both directions. 
 
Table 4.9 Primers used to clone 1.3kb of IDO promoter region. 
Sequence 
description 
Sequence 
Forward:              GGGTTTGCTAGCTCAATATTTTATTTGTAGTG 
                                  NheI 
 
Reverse: 
              
             TTTTTTCTCGAGTCTTGTAGTCTGCTCCTCTG 
                                 XhoI 
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Figure 4.9 Plasmid map of pGL4. 10[luc2] vector used to clone 5’-flanking region of 
INDO gene. 
 
4.3.5 In vitro luciferase reporter experiment 
 After the insert sequence was verified by independent sequencing and 
restriction enzyme digestion, its activity was tested by luciferase reporter gene assay 
HEK293 and SkBr3 cell lines. To control for transfection efficacy, we used the 
Renilla luciferase reporter plasmid (pRL-SV40) was used. HEK293 and SkBr3 cells 
were plated in 12-well plates 1 day before transfection. On the day of transfection, 
cells were washed twice with Phosphate Buffered Saline (PBS) solution and replaced 
with serum-free DMEM media. Cells were transfected using Lipofectamine™ LTX, 
Plus™ reagent (Invitrogen; Carlsbad, CA) with 250 ng of respective constructs and 5 
ng of Renilla Luciferase were co-transfected (a plasmid containing the 
cytomegalovirus promoter upstream of the Renilla Luciferase gene to normalize for 
transfection efficiencies). After 4 hr of incubation at 37ºC, a complete medium 
described above added, and cultured for an additional period of 24 hr at 37ºC.  
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Transfections were performed in duplicate, and repeated on at least 3 different days. 
For the dose dependent IFN-γ treatment of cells, four different doses used (0, 50, 250 
and 500 IU/ml). Measurement of luciferase activity was performed 24 hr after IFN-γ 
exposure using the Luciferase Assay Kit (Promega; Madison, WI) according to the 
manufacturer's protocol. Briefly, cells were washed with PBS solution, 100 μl of 
Passive Lysis Buffer (Promega; Madison, WI) was added to each well, and cells were 
incubated for 10 min at room temperature in an orbital shaker. Luciferase assays were 
performed using 20 μl aliquots of supernatant in a Sirus Luminometer (Berthhold 
Detection Systems, Pforzheim, Germany). Each lysate was measured twice. 
Luciferase activities were normalized for Renilla luciaferase activity in each extract 
to correct for transfection efficiency, and reporter gene expression was expressed in 
relative light units. The luciferase activity of each construct was compared with that 
of the wild type promoter at base line and after interferon treatment.  
 
4.3.6 Statistical analysis 
Data are expressed as mean ± SD, and statistical analyses were performed 
with the SPSS statistical program. One-way analysis of variance with the Dunett t-test 
was used to evaluate the difference between wild type and variants. A p-value less 
than 0.05 was considered significant. 
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CHAPTER 5 
Results  
 
5.1 Specific Aim 1: To identify indoleamine 2,3-dioxygenase genetic polymorphisms 
in the coding region that affect enzyme expression and/or activity and to evaluate the 
mechanisms by which these variants influence activity. 
The series of experiments described in this study began with the resequencing 
of the INDO gene using 96 samples obtained from the Coriell DNA repository 
(Camden, NJ). Of these samples 48 were African American (AA) and 48 were 
Caucasian (CA). These DNA samples were obtained from unrelated individuals 
without any known hereditary diseases. Since these subjects have consented for their 
DNA to be used for a variety of discovery purposes, these DNA samples are 
frequently used for identifying common genetic variants in the human population. All 
10 exons were resequenced, including splice junctions, as well as approximately 100 
bp of the 5’-untranslated region of the gene.  
In these samples, we identified 17 genetic variants in INDO gene. The detailed 
information on these variants is in Table 5.1. Eight of the variants were observed 
exclusively in the African American samples, 4 exclusively in the Caucasians 
samples and 5 in both populations. Allelic frequencies of 1 of the 9 newly identified 
intronic SNPs were greater than 36%; one in putative intron/exon splice junctions, 
which may alter the INDO mRNA processing. We also identified four variants that  
change the predicted IDO amino acid sequence; three are nonsynonymous SNPs and 
one is a 9 bp deletion.  
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In total, 5 of the 48 samples (~10%) of the African American samples 
contained nonsynonymous variant alleles (Table 5.1). Three nonsynonymous SNPs 
and one 9 pb deletion were observed only in the African American population; each 
of which was present in only a single heterozygous sample. These variants resulted in 
changes in amino acid Ala4Thr, Arg77His, Leu197Ile and the 9 bp deletion replaced 
Ala-Leu-Leu-Glu with Asp. The presence of these variants was verified by 
performing independent PCR amplification followed by sequencing.  
 The variants observed during this resequencing study were comparable to 
those present in the publicly accessible databases. A total of 43 human INDO variant 
sequences had been deposited in the SNP database (www.ncbi.nlm.nih.gov/SNP). Of 
these, 26 variants were located in introns, 2 were in the 3’-flanking region and 9 
SNPs near the 5’ UTR. Only 7 of the variants were observed during our resequencing 
studies. The remaining 36 publicly available variants were not observed in our sample 
cohort. Therefore, of the 17 INDO polymorphisms that we observed, 10 of the SNPs 
are novel. These results now make it possible to test the hypothesis that IDO genetic 
polymorphisms might contribute to individual variation in IDO expression and 
tryptophan metabolism. 
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Table 5.1 Genetic polymorphisms in the INDO gene. 1The nucleotide positions 
referred to are relative to the translation start site. The first nucleotide of the 
translation initiation codon assigned the number (+1). The numbering is based on 
accession # X_17668. Allelic frequencies were calculated as the number of variant 
alleles divided by the total of 96 alleles (48 subjects) in each group.  
Allelic 
Frequency 
   
Position1 
 
Exon 
/Intron 
   
Base pair change 
 
Location 
/Alteration 
AA CA
-89 Ex 1 gataaa*[C  >  T]tgtggt 5’ UTR 3 0 
+10 
rs#35059413 
Ex 1 gcacac[G  >  A]ctatgg Ala4Thr 2 0 
+4211 
rs#35099072 
Ex 3 cacagc[G  >  A]ccttgc Arg77His 1 0 
+6180 Int 5 taaggc[C  >  T]cctgac Intron 15 20 
+8545 Int 5 ttgaaa[C  >  T]taaaat Intron 1 0 
+8624 Int 5 caattt[C  >  T]ctcagg Splice junction 19 27 
+8733 Int 6 aaagta*[C  >  A]gtctat Intron 0 1 
+9598 Ex 7 actttg*[C  >  A]taaagg Leu197Ile 1 0 
+9605 Ex 7 *GCTGTTGGA 
Deletion 
Ala-Leu-Leu-Glu  
> Asp 
 
1 0 
+9674 Int 7 tgcagt*[G  >  A]caatag Intron 0 2 
+10917 Int 8 gtccct*[A  >  G]atatcc Intron 1 0 
+10957 Int 8 caaaaa*[T  >  G]tcacat Intron 36 2 
+11309 Int 8 ctctga[T  >  C]agctgg Splice junction 1 0 
+13855 Int 9 atgctg[T  >  C]gacctc Intron 25 39 
+13863 Int 9 acctcc*[G  >  A]tatttc Intron 1 1 
+13872 Int 9 tttcct*[C  >  A]tttctc Splice junction 0 1 
+14444 Int 10 cacaaa*[C  >  A]taatac Intron 0 1 
African American (AA) and Caucasian (CA). *Genetic variants not in public 
databases. 
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5.1.1 Bioinformatics analysis 
 After obtaining reliable sequencing data, we outlined computational 
approaches for in silico analysis of IDO genetic variants. The first step in this series 
of experiments involved analysis of the sequencing data in order to predict the  
functional significance of these amino acid variations. To do this we performed a 
comparative genomic analysis of INDO gene.  
The first method used was a FASTA algorithm to compare the human INDO 
gene with four other non-human species; we were able to identify evolutionarily 
conserved residues as highlighted in Figure 5.1 and Table 5.2. The Arg77 and two 
amino acids in the 9 bp deletion (Ala-Leu) were conserved among all 4 species.  
 
Figure 5.1 Sequence alignments of IDO orthologues. CLUSTALW alignment of 
amino acid sequences for Human (NP_002155), Dog (XP_532793), Mouse 
(NP_032350), Rat (NP_076463) and Cow (XP_582707). 
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Table 5.2 Indoleamine 2,3-dioxygenase comparative genomics: amino acid 
conservation for human IDO polymorphic residues. 
Variant alleles 
 
 
Amino acid 
 
 
Conservation 
Exon 1 
 
 
Ala4Thr 
 
 
U 
Exon 3 
 
 
Arg77His 
 
 
C 
Exon 7 
 
 
Leu179Ile 
 
 
U 
Exon 7 
 
(9 base pair deletion) 
199-200-201-202 
Ala-Leu-Leu-Glu >Asp 
 
 C   U@ 
Human A R L ALLE 
Mouse P R E ALHD 
Rat P R E ALCS 
Dog L R K ALHY 
Cow P R Q ALLE 
Amino acid locations of variant residues in human indoleamine 2,3-dioxygenase are shown. Data for 
four non-human species are listed. Those amino acids which are conserved among species are 
highlighted.C-Conserved and U-unconserved. @ Partially conserved (Ala-Leu) conserved, but not 
(Leu-Glu); 
 
The second bioinformatic method used was PolyPhen (Polymorphism 
Phenotyping). PolyPhen predicts the impact of an amino acid substitution on protein 
structure and function. To make this prediction, it uses both phylogenetic and 
structural information. PolyPhen predicted that the Arg77His variation would be 
potentially damaging (Table 5.3). It also predicted that changing the Arg77Lys residue, 
which has similar physical and chemical properties would also be damaging. It 
predicted that the Leu179Ile would be benign. The Ala4Thr could not be analyzed with 
this software because that region of the molecule was not included in the crystal 
structure. Likewise, the exon 7 deletion could not be analyzed by this software 
because it only works for single amino acid changes. 
The third method tested was SIFT; it is an algorithm that assigns scores to 
changes in amino acids on the basis of both residues involved. Using this method, the 
Ala4Thr and the Arg77His were predicted to be intolerant. The deletion of a 9 bp  
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fragment in exon 7 replaces four predicted amino acids at position 199-202 (Ala-Leu-
Leu-Glu) with an Asp. This minor allele was observed in the 48 African American 
samples (96 alleles), an allelic frequency of 1%. Using the SIFT prediction tool, the 
Leu179Ile variant was predicted to be tolerant. These programs are exciting new tools. 
They may be useful for research investigating a protein by suggesting regions that 
may be more interesting than others to be studied thoroughly for their function. The 
few variants that we showed indicate that, in silico investigations should never 
replace real functional testing of the protein. The main reason that confidence in these 
programs should be limited is that they can only minimally consider interactions of 
the particular protein with other molecules, such as chaperones; or part of the protein 
involved in signaling.  
Table 5.3 Human indoleamine 2,3 dioxygenase (IDO) variant amino acid “scoring”.                                
hIDO Amino acid changes Scoring system for variant residues 
  PolyPhen SIFT 
Wild-type - - - 
Exon 1 Ala4Thr NP IT 
Exon 3 Arg77His POS IT 
Exon 3 Arg77Lys# POS IT 
Exon 7 Leu179Ile BN T 
Exon 7 Ala-Leu-Leu-Glu > 
Asp 
ND IT/T 
The table summarizes the results from PolyPhen (Polymorphism Phenotyping) SIFT (Sorting 
Intolerant From Tolerant), # this variant does not occur naturally; (NP) not predicted; (POS) possibly 
damaging; (BN) benign; (IT) intolerant; (T) tolerant 
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5.1.2 In vitro analysis 
We next addressed the possible functional consequences of INDO 
nonsynonymous variants. Based on the bioinformatic analysis above, these appeared 
to be most likely to have functional effects on IDO enzyme activity. We focused our 
studies on the nonsynonymous SNPs Ala4Thr and Arg77His and the 9 bp deletion 
(Figure 5.2). 
 
 
Figure 5.2 Functionally tested indoleamine 2,3-dioxygenase genetic variants. 
The figure shows a schematic representation of human INDO gene with the location 
of the coding polymorphisms located by arrows. The boxes numbered 1-10 represent 
the exons. The lines connecting the boxes represent the introns. The arrow in exons 1 
and 3 represent the nonsynonymous SNPs. The arrow in exon 7 represents the 9 bp 
deletion. Two functionally tested nsSNPs in the coding region of IDO, Ala4 (GCT) 
replaced with Thr (ACT) and Arg77 (CGC) replaced with His (CAC). Nucleotide 
sequences are shown for the start and stop codon of hIDO as well as the respective 
amino acid changes. 
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Expression constructs for the three naturally occurring IDO coding variants 
(Ala4Thr, Arg77His, 9 bp deletion) and the Arg77Lys as a control construct for 
Arg77His variant, as well as the wild type were expressed in COS-7 and HEK293 
cells. We tested the functional effects of the genetic variants on the IDO enzyme 
activity.  
The wild-type and variant cDNAs were expressed in COS-7 and HEK293 
cells using the pcDNA3 vector. These cells were used because they have very low 
endogenous IDO activity and the transfected wild-type IDO is highly active in these  
cell lines. Since they are a mammalian cell line, they also contain the post-
translational modification machinery and protein degradation systems that may affect 
the activity of the variant IDO enzymes. To determine the IDO enzyme activity, we  
analyzed the tryptophan and kynurenine concentrations of the cultured media 
harvested 48 hr after transfection. Some amount of tryptophan from the culture media 
is going to be used for protein synthesis by the cells. 
Representative chromatograms from wild type and variant IDO proteins are 
shown in (Figure 5.3). Chromatograms from the wild type and Ala4Thr constructs 
showed the complete metabolism of tryptophan in the culture media and increased 
kynurenine peak. In contrast there were no reduction in tryptophan peak in the 
chromatograms from Arg77His and 9 pb deletion constructs (Figure 5.3). 
As expected, the transfection of the wild-type cDNA was highly active. The 
cultured media contained reduced tryptophan and elevated kynurenine concentrations. 
The expression of the Ala4Thr resulted in similar tryptophan metabolism. In contrast,  
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the Arg77His transfected cells had very little metabolic activity. Relative to the wild-
type cDNA, the Arg77His kynurenine production was reduced by >90% (Figure 5.4). 
When the Arg at position 77 was replaced by a Lys, another basic and hydrophilic 
amino acid, the activity was also reduced, but to a lesser extent. Even though Arg and 
Lys have similar physicochemical properties replacing of Arg77His with Lys did not 
restored IDO activity (Figure 5.4). These data suggest that Arg at position 77 play a 
significant role in IDO activity. This amino acid is also conserved among all the four 
species analyzed.  
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Figure 5.3 Representative chromatograms showing the separation of tryptophan and 
kynurenine using HPLC from wild type and variant IDO transfected cells. Cultured 
medium from COS-7 cell line transiently transfected with (from top) wild type, 
Ala4Thr, Arg77 and exon7-9 bp deletion IDO cDNA was collected after 48 hr, 
extracted with trichloroacetic acid and the supernatant was loaded on an HPLC. X 
axis is time in minutes; Y axis is millivolt signal from the detectors, the right panel 
shows ultraviolet kynurenine detection at 360 nm, the right fluorescence, excitation 
=285 nm, emmission=365 nm for tryptophan detection.  
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Figure 5.4 The effect of IDO variants on kynurenine formation in COS-7 cells. IDO 
activity was determined by measuring kynurenine (top) and tryptophan (bottom) 
concentrations in COS-7 cells after a 48 hr transient transfection of IDO cDNAs. 
Tryptophan and kynurenine measured by HPLC. All data are presented as mean ± SD 
(n=3). *, value (p<0.05) significantly different from the value obtained for the wild 
type compared with Ala4Thr. **, value (p<0.001) significantly different from the 
value obtained for the wild type compared with Arg77His. Arg77Lys variant, which 
was not observed in the general population, was a control for the His77 variant. 
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Increasing the amount of plasmid DNA in the transfection resulted in a dose-
dependent increase in the kynurenine formation in cells transfected with the wild type  
and Ala4Thr variant IDO constructs. The dose dependent increment of plasmid DNA 
did not affect the formation of kynurenine in the Arg77His variant (Figure 5.5). Both 
wild type and Ala4Thr IDO showed a time dependent increase in the formation of 
kynurenine, but not the Arg77His variant (Figure 5.6). 
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Figure 5.5 The effect of IDO variants on kynurenine formation in HEK293 cells 
with increasing plasmid concentrations. IDO activity was determined by measuring 
kynurenine (top) and tryptophan (bottom) concentrations in HEK293 cells after a 48 
hr transient transfection of IDO cDNAs with increasing concentration expression 
vector. Tryptophan and kynurenine measured by HPLC. All data are presented as 
mean (n=2). Arg77Lys variant, which was not observed in the general population, was 
a control for the His77 variant. 
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Figure 5.6 The effect of transfection time on kynurenine formation in HEK293 cells 
in a time dependent manner. IDO activity was determined by measuring kynurenine 
(top) and tryptophan (bottom) concentrations in HEK293 cells after 12, 24, 48 and 
72 hr transient transfection with 0.5 μg of IDO expression vectors. Tryptophan and 
kynurenine measured using HPLC. All data are presented as mean ± SD (n=3). 
Arg77Lys variant, which was not observed in the general population, was a control 
for the His77 variant. 
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Figure 5.7 The effect of IDO variants on kynurenine formation in HEK293 cells. 
IDO activity was determined by measuring kynurenine (top) and tryptophan (bottom) 
concentrations in HEK293 cell media 48 hr after transient transfection with the IDO 
cDNAs. Tryptophan and kynurenine measured by HPLC. All data are presented as 
mean ± SD (n=3), **, value (p<0.001) significantly different from the value obtained 
for the wild type compared with other variants. 
 
A similar reduction in IDO activity was observed (Figure 5.4 and 5.7) in 
cDNA’s expressed in the COS-7 and HEK293 cells using both plasmids (pCMV-
SPORT6 and pcDNA3). To verify that the variant IDO mRNAs were being equally 
expressed from the plasmids in the transient transfected COS-7 and HEK293 cells, 
we also quantified the IDO mRNA expression. To test the hypothesis that altered IDO  
activity is because of reduced mRNA expression we used end-point RT-PCR analysis. 
The data suggest that altered IDO activity in Arg77His and the 9 bp deletion variants 
were not due to reduced mRNA expression, but it could also potentially be, because 
of decreased translation or altered post- translational regulation (Figure 5.8). 
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Figure 5.8 IDO mRNA expression in COS-7 and HEK293 cells. The levels of IDO 
mRNA in COS-7 cells transfected with blank pcDNA3, wild type, exon 1- Ala4Thr, 
exon 3- Arg77His and exon 3 -Arg77Lys IDO cDNA were measured by an end point 
PCR (top). The levels of IDO mRNA in HEK293 cells transfected with blank 
pcDNA3, wild type, exon 1- Ala4Thr, exon 3- Arg77His, exon 7- 9 bp deletion and 
exon 3 -Arg77Lys IDO cDNA were measured by an end point PCR (bottom). A 
representative gel of 3 replicates of products. GAPDH was used as the control gene. 
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To assure that the differences in the enzyme activity in the variant IDO 
constructs were not due to artifacts in plasmid production, we replicated these  
studies in several ways. Constructs expressed in two different cell lines using two 
different types of plasmids as described above suggest that the enzyme activity were 
similar in both cell lines tested COS-7 and HEK293 (Figure 5.4 and 5.7).  
To be certain that the concentrations of wild-type and variant plasmids used 
for the transfections were similar, we quantified the working dilutions of the plasmids 
using DNA 7500 chip in the Agilent Bioanalyzer 2100 (Figure 5.9). In addition we 
also used multiple preparations of the plasmids in the replicates to assure that the 
reduced activity was not due to an artifact in any of the preparations. 
 
Figure 5.9 Representative pseudo gel from Agilent 2100 Bioanalyzer. From the left a 
serial dilution of plasmid from exon-1 Ala4Thr variant showed the same band 
intensity as the exon-3 Arg77His variant in the right (top). A chromatogram showing a 
corresponding peak from bands of respective samples (bottom). 
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Part of this variability could be a result of altered mRNA expression levels 
transfected cells. To assess this variability, we analyzed our transfected cells using a 
quantitative RT-PCR assay to determine the effect of the nsSNPs on the IDO RNA 
concentration. The differences in the mRNA expression levels of the variant IDO 
mRNAs were not sufficient to account for the large decrease in IDO enzyme 
activities of the Arg77His and the 9 bp deletion. Similar mRNA expression was seen 
in the transfected COS-7 and HEK293 cells (Figure 5.10).  
 
 
Figure 5.10 IDO mRNA expression in HEK293 cells. The levels of IDO mRNA in 
HEK293 cells transfected with the wild type, exon 1- Ala4Thr, exon 3- Arg77His, 
exon 7- 9 bp deletion and exon 3 -Arg 77Lys IDO cDNA were measured by real-time 
SYBR Green RT-PCR. Samples are normalized using GAPDH and the relative fold 
change was calculated based on the 2-∆∆Ct method. All data are presented as mean ± 
SD (n=3). 
 
To assess the effects of these genetic variants on the expression of the IDO 
protein, we harvested HEK293 cells transiently transfected with IDO expression 
vectors and analyzed them by Western blot. We detected immunoreactive IDO  
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protein in the cells transfected with the wild-type and the Ala4Thr plasmids; however, 
the Arg77His and the Arg77Lys showed reduced protein level and no protein was 
detected for the 9 bp deletion. The negative control, pcDNA3 vector also had no 
detectable expression (Figure 5.11). These results were consistent with the enzyme 
activity results, which indicate that the reduced enzyme activity of the variant 
proteins may be due to altered stability of the variant proteins. 
Since the reduced IDO immunoreactivity on the Western blot could be due to 
reduced antibody binding to the variant IDO protein, we created cDNAs for the wild-
type and variant proteins that have an HA-tag incorporated into the C-terminal end of 
the IDO protein. Similar to the results of the transfections without the HA-tag (Figure 
5.11), cells transfected with the HA-tagged cDNAs encoding the Arg77His had 
reduced tryptophan metabolic activity; likewise, the 9 bp deletion totally abolished 
tryptophan metabolism (Figure 5.11). Furthermore, similar to the anti-IDO Western 
blots, when using the anti-HA tag antibody, the cells transfected with the cDNAs 
encoding for the Arg77His and Arg77Lys variants had reduced immunoreactive HA-
tagged IDO protein; and, no protein as detected for the 9 bp deletion. We stripped the 
blots and probed them using the anti-IDO antibody and obtained similar results to the 
anti-HA tag Western blots (Figure 5.11). 
Levels of IDO protein, as detected by Western blot analysis, did not correlate 
with the IDO transcript data. For example, no IDO protein was detected for the 9 bp 
deletion and there was a significant reduction in the IDO protein for the Arg77His 
variant (Figure 5.9). However, comparable amount of transcript was detected from all 
constructs. Therefore, the alterations must be at the posttranscriptional level.  
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Figure 5.11 IDO expression and activity in HEK293 cells. The HEK293 cells were 
transiently transfected with plasmids containing cDNAs for HA-tagged wild type, 
Ala4Thr, Arg77His, 9 bp deletion, and Arg77Lys IDO proteins (top). The amounts of 
the respective IDO proteins were determined by Western blot using an anti-IDO and 
anti-HA-tag antibodies. Kynurenine production by the HEK293 cells following 
transfection with the IDO cDNAs (bottom). Values are the concentrations of 
kynurenine in the media 48 hr after transfection. All data are presented as mean ± SD 
(n=3), **, value (p<0.001) significantly different from the value obtained for the wild 
type compared with other variants. 
 
One of the limitations of these types of studies is that the activities were 
evaluated by transient expression systems. To overcome this issue, we established 
stable cell line expressing IDO wild type and variant constructs and assessed IDO 
activity using these cell lines. The results from the stable cell lines were also  
consistent with the transient expression. This provides additional support that the low 
metabolic activity from the Arg77His was not due to reduced IDO transient expression. 
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Up to now, we characterized the formation of kynurenine in COS-7 and 
HEK293 cells transiently expressing different IDO constructs. IDO activity was 
assessed based on the consumption of tryptophan in the culture media (~80 μM) or by 
the formation of kynurenine (Figures 5.4. to 5.7). Using a quantitative western blot 
analysis, corrected for equivalent amount of immunoreactive IDO protein, enzyme 
kinetic parameters were determined for the wild type and variant proteins. The 9 bp 
deletion variant was not included in this experiment, since it does not give any 
detectable IDO activity or protein. Each variant’s ability to convert tryptophan into 
kynurenine was determined and compared to the wild type activity.  
In an effort to reveal potential subtle differences in the tryptophan metabolism 
among the three IDO variants, analysis of tryptophan metabolism was studied using a 
range of substrate concentrations (Figure 5.12). A representative Western blot for the 
optimization of equal IDO protein loading is shown in (Figure 5.12 top). These 
observations represent additional evidence that the alteration of only a single amino 
acid as a result of genetic polymorphism can significantly alter the level of protein.  
Although we observed reduced IDO protein levels due to single amino acid 
changes, variability could also be a result of altered enzyme kinetic properties.  
Therefore, we determined the kinetic parameters of wild type, Ala4Thr and Arg77His 
variants using cell lysate from cells transfected with respective constructs. First, we 
tested a range of protein concentrations (0, 50, 100 and 200 mg) to choose the  
optimum protein concentration for the kinetic study (Figure 5.12 bottom). Since IDO 
can display profound substrate inhibition at high substrate (tryptophan) 
concentrations, these experiments were conducted in two stages. During the first 
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stage of experiment, a wide range of substrate concentrations were tested. In the next 
step, based on the results of the initial studies, the concentration range narrowed to 
the values appropriate for the determination of Km and Vmax. The Arg77His variant 
showed a significant reduction in Vmax compared to wild type and Ala4Thr variant 
(Figure 5.13). The results obtained also showed that both Arg77His variants resulted 
in a four fold reduction in the intrinsic clearance. The Ala4Thr variant Vmax and Km 
were similar to the wild type (Figure 5.13 and Table 5.4). 
The reduction in catalytic activity of Arg77His variant was accompanied by 
changes in the Km value which also affected the intrinsic clearance. The Ala4Thr 
showed the same metabolism profile as the wild type; these data were consistent with 
the results from cell culture studies (Figure 5.4 and 5.7). Consistent with the transient 
expression data, the Arg77His variant showed a significant reduction in the 
metabolism of tryptophan; this suggests that the Arg77His residue is important for 
IDO activity. Relative to the wild type or the Ala4Thr variant the Arg77His variant had 
changes in both Vmax and Km. The Arg77His variant showed lower apparent substrate  
affinity as reflected by the higher Km values compared to the wild-type and the 
Ala4Thr variant enzyme. 
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Figure 5.12 Exon 3 Arg77His variant has a reduced activity. Immunoreactive 
recombinant human IDO expressed in HEK293 cells and enzyme activity. The 
HEK293 cells were transiently transfected with plasmids containing IDO cDNAs for 
HA-tagged wild type, Ala4Thr and Arg77Lys respectively (top). The amounts of the 
respective IDO proteins were determined by Western blot using an anti-HA-tag 
antibody. The formation of kynurnine by respective IDO constructs with increasing 
normalized units of equivalent IDO protein (bottom). 
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Figure 5.13 Kinetics of tryptophan metabolism. Recombinant wild type and variant 
IDO proteins (100 mg) were incubated with a range of tryptophan concentrations (0, 
3.12, 6.25, 12.5, 25, 50, 100, 200 μM) for 1hr and formation kynurenine measured 
using a calorimetric assay, as described under material and methods. Representative 
fitted lines are depicted; parameters estimates were obtained by fitting the kinetics 
models to actual data points. 
 
Table 5.4 Kinetic parameters estimated for tryptophan metabolism by wild type and 
variant IDO proteins.  
Estimate        Wild type        Ala4Thr            Arg77His            Arg77Lys 
Vmax 52.2 ±1.0 53.0 ± 5.6 19.7 ± 3.1** 22.7 ± 6.9** 
Km 18.0 ± 4.5 23.4 ± 9.1 29.6 ± 11.8 34.2 ± 18.2 
Vmax/Km 3.0 ± 0.8 2.4 ± 0.7 0.70 ± 0.2* 0.78 ± 0.3* 
Data are expressed as estimate ± SD., n=3, estimate unites are as follows: Vmax, pmol/hr/mg; 
Km, micro molar; Vmax/Km, ml/min/mg. **, value (p<0.001) and * (p<0.005) significantly 
different from the value obtained for the wild type compare with Arg77 variant.  
 
 
The reduction in IDO expression and activity in the Arg77His variant (Figure 
5.11 and 5.13) could be due to accelerated degradation. To assess this possibility, we 
used the TNT-RRL system to transcribe and translate wild type and variant proteins to 
in vitro. IDO activity was determined by using recombinant protein translated in the  
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TNT-RRL system. In contrast to the other experiments, the Arg77His variant exhibited 
IDO activity that was similar to the wild type (Figure 5.14). This was a surprising 
observation, because in the transient expression system the Arg77His variant exhibited 
a dramatic reduction in IDO activity. 
 
 
Figure 5.14 IDO enzyme activity assessment using protein translated in the  
rabbit reticulocyte lysate [TNT-RRL] system. IDO activity was determined by 
measuring kynurenine concentration using IDO protein translated in the rabbit 
reticulocyte lysate (RRL) system. Kynurenine measured by HPLC as described in the 
methods section. IDO activity was determined by measuring kynurenine in the cell 
lysate, values shown are mean ± SD for three independent experiments **, values 
(p<0.001) and * (p<0.005) significantly different from the value obtained for the wild 
type compared with other variants. 
 
 
Protein degradation inhibitors and IDO activity  
 
Since the TNT-RRL results differ from the transient transfection data, we 
explored possible mechanisms. One possibility is that the hemin in the TNT-RRL 
system might affect IDO activity. This was a likely scenario since the results from our 
previous studies demonstrated that the Arg77His and 9 bp deletion resulted in the  
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reduction of both protein expression and enzyme activity. Furthermore, it has been 
shown in a number of studies that coding variants potentially result in structural 
disruption and misfolding of newly translated proteins 109. One of the most common 
mechanisms by which misfolded proteins are removed from the cell is by accelerated 
degradation. This degradation is usually through the Ubiquitin Protesome Pathway 
(UP)145. The misfold proteins can also form aggregates 109. To keep a dynamic 
balance between protein degradation and aggregation mammalian cells have 
developed a highly regulated protein quality control mechanism 102, 103, 109 (Figure 
2.1). 
To further analyze this observation, transiently transfected cells were treated 
with hemin in a dose dependent manner. The effect of hemin in restoring IDO activity 
in the Arg77His construct became apparent for the first time during the use of in vitro 
translated proteins using TNT-RRL system (Figure 5.14). This in vitro translation kit, 
rabbit retculocytes are treated with 20 μM hemin (Figure 5.15), because it suppresses 
an inhibitor of the initiation factor elF2α. In the absence of hemin, protein synthesis 
in the Reticulocyte Lysate System will cease after a short period of incubation 146. 
 
We tested if hemin has the same effect in transiently transfected HEK293 cells. 
In cells transfected with Arg77His hemin showed a dose dependent increase in the 
formation of kynurenine (Figure 5.16 and 5.17). Hemin restored IDO activity in  
the Arg77His variant without increasing the immunereactive protein (Figure 5.16). 
This data suggest that hemin might stabilize the Arg77His variant IDO protein and 
increased formation of kynurenine without affecting protein concentration. 
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Figure 5.15 Molecular structure of hemin (Adapted from Sigma-Aldrich). 
 
 
 
Figure 5.16 The effect of exposure to increasing concentration of hemin on  
IDO activity. HEK293 cells transfected with a wild type and variant IDO constructs 
and treated with increasing concentration of hemin. IDO activity was determined by 
measuring kynurenine (top) and tryptophan (bottom) concentrations in HEK293 cell 
media after 24 hr. Tryptophan and kynurenine measured by HPLC. Values shown are 
mean ± SD for three independent experiments **, value (p<0.001) significantly 
different from the value obtained for the wild type compared with other variants. 
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Since hemin can affect multiple cellular processes, we also tested additional 
proteosomal inhibitors to confirm that the effect was through the proteosome 
inhibition (Figure 5.16). Two specific proteosomal pathway inhibitors were tested.  
The first one MG132 is an aldehyde -based reversible inhibitor. The second is 
lactocystin, a lactone- based irreversible inhibitor. Neither inhibitor changed IDO  
activity in any of expressed IDO proteins (Figure 5.17). We also tested the lysosomal 
pathway inhibitor, chloroquine. It did not affect tryptophan metabolism in the 
Arg77His expressing cells (Figure 5.18). 
 
The results presented in this study strongly suggest that the mechanism 
underlying the altered protein expression in the Arg77His and the 9 bp deletion is a 
translational or post-translational event. The 9 bp variant yielded virtually no 
detectable protein when expressed in HEK293 cells (Figure 5.11). Furthermore, data 
from the Arg77His variant showed a decreased level of protein, which at least in part, 
could be due to accelerated degradation pathway. Exposure of cells with proteasome 
pathway inhibitors (MG132 and lactocystin) after transient transfection with Arg77His 
construct did not increase in IDO activity (Figure 5.17). These proteasome pathway 
inhibitors bind to the 26S-proteasome and prevent degradation of short –lived 
proteins 147. Likewise inhibition of the lysosomal pathways with chloroquine did not 
affect the Arg77His activity (Figure 5.18). 
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Figure 5.17 The effect of proteasome inhibitors MG132, lactocystin and hemin on 
Arg77His activity. IDO activity was determined by measuring kynurenine (top) and 
tryptophan (bottom) concentrations in HEK293 cells treated with increasing 
concentration of proteasome inhibitors after a transient transfection with the Arg77His 
construct. Tryptophan and kynurenine measured by HPLC. Values shown are mean ± 
SD for three independent experiments. 
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Figure 5.18 The effect of lysosomal pathway inhibitor on IDO activity in HEK293 
cells. IDO activity was determined by measuring kynurenine (top) and tryptophan 
(bottom) concentrations in HEK293 cells transiently transfected with wild type 
exon3 (Arg77His) and exon7 (9 bp deletion) IDO constructs and treated with 
increasing concentration of lysosomal pathway inhibitor. Tryptophan and kynurenine 
measured by HPLC. Values shown are mean ± SD for three independent experiments. 
 
Hemin increased IDO activity in HEK293 cells transiently transfected with 
the Arg77His IDO variant in a dose dependent manner (Figures 5.16, 17 and 21). The 
increase in IDO activity occurred without increasing detectable immuno reactive IDO 
protein as measured by Western blot (Figure 5.16). This suggests that hemin might be 
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working through another non proteosomal mechanism. One such mechanism may be 
through restoring the cellular heme concentration. Since heme is required for IDO  
activity incorporation of heme into the IDO protein could be the rate limiting factor in 
IDO activity in the Arg77His variant.  
To address this possibility we assessed heme concentrations in HEK293 cells 
transfected with wild type and variant constructs. Heme concentrations were 
significantly lower in HEK293 cells transfected with the variant constructs compare 
with wild type and Ala4Thr variant. Heme concentrations for the variants were in the 
2-5 μM range, but for the wild type and Ala4Thr were up in the 30-35 μM (Figure 
5.19). The interesting finding in this study was that the heme concentration correlated 
with the kynurenine production. Furthermore, the addition of hemin, which can 
substitute for heme, restored the IDO activity. This provided strong evidence that 
heme incorporation into the IDO may be a limiting factor.  This promoted further 
investigation into the role of endogenous heme in the IDO activity (Figures 5.19 
bottom). 
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Figure 5.19 The effect of exposure to increasing concentration of hemin on IDO 
activity and heme concentration. IDO activity and heme concentrations were 
assessed after the transfection of HEK293 cells with a wild type and variant IDO 
constructs. IDO activity was determined by measuring kynurenine (y-axis) and heme 
(x-axis) concentrations in HEK293 cell media 24 hr after hemin exposure (top) only 
vehicle and (bottom) vehicle, 3.75, 7.5 and 15μM. Kynurenine was measured in the 
media and heme concentration measured in the cell lysate from respective constructs. 
Kynurenine and heme were measured using a plate reader. IDO activity determined 
values are shown as means ± SD for three independent experiments. **, value 
(p<0.001) significantly different from the value obtained for the wild type compared 
with Arg77His variant. 
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Since de novo synthesis of heme is important for IDO activity, we further 
evaluated the impact of the Succinyl acetone is a potent heme synthesis inhibitor 
succinylacetone (SA). Succinyl acetone is an inhibitor of 5-aminolevulinic acid 
dehydratase, the second enzyme involved in heme synthesis 148. To examine the role 
of SA, HEK293 cells were pretreated with 500 μM SA for 12 hr; cells were then 
transiently transfected with wild type or Arg77His variant IDO. IDO activity was 
assessed by measuring kynurenine formation in the culture media (Figure 5.20). 
 In the wild type cells, the inhibition of heme synthesis substantially reduced 
IDO activity. In the Arg77His cells, the SA completely abolished the formation of 
kynurenine (Figure 5.20). This experiment showed that heme synthesis is necessary 
for optimal IDO activity. The effect of SA on cell viability has tested using Trypan 
Blue Stain and there was no difference between the SA and vehicle treated cells. 
Since we did not analyz IDO mRNA after SA treatment it is possible that SA could 
affect the mRNA concentration. Next we measure heme concentration in the cell 
lysates after SA treatment and correlated it with IDO activity (Figure 5.21). The 
inhibition of IDO activity in the Arg77His transfected cells were reversed by addition 
of hemin (Figure 5.19). The hemin effect was dose dependent (Figures 5.16, 5.19 and 
5.21). Since, hemin did not increase the protein concentration; it appears not to be 
through the proteasome pathway (Figure 5.18). Hemin also restored IDO activity in 
cells transiently transfected with the wild type IDO construct at low dose. SA clearly  
reduced IDO activity in the wild type, as the Arg77His variant (Figures 5.20 and 21). 
Together, these results suggest that hemin restores the Arg77His IDO activity by  
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increasing the incorporated heme into IDO in the cell and increases the modification 
of the apo to holo enzyme. Hemin did not increase heme concentration in cell that 
were pre treated with SA (Figure 5.21) compared to cells that were not treated (Figure 
5.19) which suggest that SA has inhibited de novo synthesis of heme and reduced the 
heme concentration (Figure 5.21). 
  
 
 
Figure 5.20 The effect of the heme synthesis inhibitor succinylacetone (SA) on IDO 
activity. IDO activity was determined by measuring kynurenine concentrations in 
HEK293 cell media 24 hr after SA treatment. HEK293 cells transiently transfeted 
with wild type and Arg77His constructs after SA treatment. The effect of SA reversed 
by hemin exposure 12 hr after transient transfection with IDO cDNAs. Values shown 
are mean ± SD for three independent experiments.  
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Figure 5.21 The effect of the heme synthesis inhibitor succinylacetone (SA) on IDO 
activity in HEK293 cells transiently transfeted with wild type and Arg77His construct 
and its response to hemin. IDO activity was determined by measuring kynurenine 
concentrations in HEK293 cell media 24 hr after 500 µM SA treatment. The effect of 
SA dose dependently reversed by hemin exposure 12h after transient transfection 
with IDO cDNAs. Values shown are mean ± SD for three independent experiments. 
 
 
Since the X-ray crystal structure of human indoleamine 2,3-dioxygenase has 
been solved 149, we were able to map the Arg77His and the 9 bp deletion to the 3-D 
structure of the IDO protein. The consequence of genetic variants in the regions that  
are directly part of a functional domain, such as substrate binding pocket of the 
enzyme, are likely to cause a more severe phenotype than variation in regions of less  
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functional importance. In the crystal structure, the first 11 amino acids were not 
determined; therefore, the Ala4Thr could not be mapped. Neither the Arg77His nor the 
9 bp deletion appeared to be part of the substrate recognition or heme binding site 
(Figure 5.22). Both variants are upstream from the highly conserved substrate 
recognition site Phe226, Phe227 and Arg231 identified by site directed mutagenesis 
experiments 149. However, it is possible that the changes indirectly alter those binding 
sites through changes in the protein folding or structure. 
The Arg77His amino acid and the first two amino acids affected by the 9 bp 
deletions were strictly conserved among vertebrate IDO orthologs. The variant 
affecting residue Ala4Thr did not show any functional impairment which is also not 
conserved among the vertebrate orthologs compared (Figure 5.1 and Table 5.2). This 
observation suggest that residues Arg77His and (199-202) Ala-Leu-Leu-Glu replaced 
by Asp due to the 9 bp deletion are important in maintaining normal IDO function. In 
our experimental system, 9 bp deletion variant abolishes enzyme function completely. 
This supports the hypothesis that conserve residues are of important for maintaining 
normal enzyme function.  
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Figure 5.22 Location of the variant positions in the human indoleamine 2,3-
dioxygenase crystal structure. Top, The ribbon representation of the overall structure 
of human Indoleamine 2,3-dioxygenase (PDB entry code 2D0T). Each monomer has 
small and large domains which create a cavity for the heme where the substrate 
binding site is located. Bottom left, Close up of the structure around the four amino 
acids (Ala-Leu-Leu-Glu>Asp) at a position 199-202. Bottom right, The single 
nucleotide polymorphism on exon 3 causes the change of Arg77His. The red and 
green are separate monomers as taken from the PDB. The yellow are the amino acids 
that are changed by the genetic variants. The red is the heme and the substrate in the 
binding site. 
 
 
 
Ala199 
Glu202 
Leu200Leu201 
Arg77His 
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5.2 Specific Aim 2: To identify genetic variants in the IDO promoter and to assess 
their functional significance. 
We resequenced portions of IDO promoter to identify and functionally 
characterize genetic variants which could affect IDO expression. 
In the present study, we identified seven novel genetic variants in the 5’-
flanking region of INDO gene (Table 5.5).  
Table 5.5 Genetic polymorphisms in the 5’-flanking region of INDO gene. 1The 
nucleotide positions referred to are relative to the translation start site. The numbering 
is based on accession NM_002164. Allelic frequencies are the number of variant 
alleles out of the 96 alleles (48 subjects) in each group.  
Position Base pair change CA (n=96) # AA (n=96) # 
-1144 cctatt (C > G)aaggaa 0          1 
-1135 agggaa(C > T)attttcc 0 3 
-1113 atgaca(G > T)gttgaa 0 3 
-1104 gttgaa(G > A)aaaaca 0 3 
-1081 ttagta(G > C)agaaata 0 4 
-742 [FOXC1] tattac(A > G)ttattag 1 0 
- 624 [GATA3] aatgct(A > G)tcattgg 1 0 
@-89 5’UTR gataaa(C>T)tgtggt 3 0 
African American (AA) and Caucasian (CA). # number of variant alleles identified in a total 
of 96 alleles (48 samples).@ This SNP discovered during the resequencing of the coding 
region (aim 1), and has functionally tested in aim 2. 
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5.2.1 Bioinformatics analysis 
The mechanisms by which IDO expression is regulated differently in different 
people remains unknown. This makes it difficult to ascertain whether variable IDO 
expression is a cause or an effect of the variability in therapy outcomes. Thus,  
knowledge concerning the molecular mechanisms involved in IDO gene expression is 
of significant importance. 
Gene expression, and in particular transcription, in eukaryotic cells is an 
important process that is under complex regulation. The complex interaction of 
transcription factors with the transcription binding motifs could be affected by genetic 
variants in the promoter of the gene.  
To identify the presence of important transcription-factor-binding sites, we 
used JASPAR and TRANSFAC software’s, we focused our search on the 1.3 kb of 
the 5’-flanking region. This 5’-flanking region revealed a variety of putative 
transcription factor binding sites (Figure 5.23 and Table 5.6). As shown in Figure 
5.23, two of the novel SNPs are located within the putative transcription factor 
binding sites FOXC1 and GATA3. When we analyze the variant sequence with these 
transcription factor binding sites the prediction were below the threshold. 
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IDO PROMOTER SEQUENCE 
                   FOXC1 
TTCCTTGAACTGATTCCCAAAGTATTAGCCTCATGAATCATGTAGTCATAAGAAACACAGTCAT 
  GAS-3    C/EBP-BETA-1                      -1144 C>G -1135 C>T        
TGTATTCTCTTTGCTGTATAATTTTGGTTTCAGTTTTCCTTACATTTCCTATTCAAGGAACATT 
         -1113 G>T -1104 G>A   ISRE-1 -1018 G>C   
TTCCTGTAAAATGACAGGTTGAAGAAAACAGCCATAATTTAGTAGAGAATAGCGCGAGAGCTAT 
  GAS-2 
TCTAGACTGTAACGAAAGCCATATGCTATCACAATTTAATTTATTTCAAGTACTAATAAGCTGA 
 
TGACAAAACAGCGATGTCTTTTAGTTTACTCACACGAACTATTTCTCTTTTCTCCTTTTGATCA 
 
TCTAGAGGAACGGGCAACTTGGTTTCTTCTTTAGCTTCCTTGTTCTCATTAAGATTGAACAATG 
 
CCTCTAAAGTGAACCACAGACTTGCATGCAAGCTGAAAACCTTTACCAAATGCAGTCTTAATTT 
                                                      -742  A>G 
GTACTTTGAGAAAAACATTTTCAAGGTATTTTATCCTTTTCTCCAACTTTTGACATATTACAAA 
                                                           FOXC1 
GTACCCAAATATGCCAGACTGTTGCCTCATCAGCCCCCCGCAGTCAGGTACAGTTAGATGCAAG 
                                           -624 A>G 
GCAATCTTCCTAAAAGTTACTTATTAGAGATGTGAGAAGGGCAAATGCTATCATTGGAAAAACT 
     C/EBP-BETA-2                              GATA3   
GACAAAAGTCCCAATAGGAAAAATAAGGAAGTGGAGAGTTACTATGTTTCTAATTTTTCATGTG 
 
CTTCTATTTTTTTCCTACTTCAGAGCCATTGACTAATAGTTGAGTATAACACAGGTTGTGTTTC 
 
CGGGCTGCTGAAACATGACACTAATATTTTCAAAGAACTGTGGAAGCCTAAAAGGAAGCCAATG 
 
AGAAATAACTAAATGAGAGTTTAGGACTGCAGCCTTCATTTTCATTCAAAGATTTAAAAGTTTC 
 
CATAAAGTAAAATGTTCTTCTCCGGCCACCTGTTTTCATAGTTCTGTGTTTTCCTTCAGGCCTT 
 
TCTGGCTTCCTATATGGCAGTAAGAAAATGATGTGCTTAATGATTACAAATTTCATATGGAATA 
                                     TRANSCRIPTION START SITE [TSS] 
CGAACTTTCAGTTTGTACATATGATGCACAGAGATGCTTTTGTGGTTTTATTGGTTTTCATATT 
 
ACAAACAAAGAAACTAGAAAATGAAACCATTCCAAAAGTGGAAGTAATTTCTCACTGCCCCTGT 
 -89 C>T         ISRE-2    C/EBP-BETA-3 
GATAAACTGTGGTCACTGGCTGTGGCAGCAACTATTATAAGATGCTCTGAAAACTCTTCAGACA 
GATA3 
CTGAGGGGCACCAGAGGAGCAGACTACAAGAATGGCACA 
                       TRANSLATION START SITE [TSS] 
 
Figure 5.23 DNA sequence of the 5’-flanking region of the INDO gene. The SNPs 
that we functionally tested are highlighted in red. The two newly identified 
transcription binding sites -742 FOXC1 and -624 GATA3 are also highlighted in red 
boxes. Transcription factor binding sites that have been characterized before (ISRE-
Interferon Stimulating Response Element, C/EBP-Beta -CCAAT/Enhancer binding 
protein-beta, GAS-Gamma activating sequence are labeled in (Blue boxes). The 
sequences covered during the 5’-flanking region resequencing are highlighted in 
yellow. The 5’-UTR region highlighted in green and it was covered during the coding 
region resequencing. 
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Table 5.6 Twenty-two putative TFBS were predicted using JASPAR (95% relative 
score threshold). Two SNPs were discovered within TFBSs: FOXC1 and GATA3. 
Start from 
upstream 
Model 
Name 
Relative 
Score 
Predicted site 
sequence 
Actual sequence 
1 FOXC1 0.958 CCAAAGTA CCAAAGTA 
2 IRF1 0.951 AAAACTGAAACC GGTTTCAGTTTT@  
3 SPIB 0.967 ACAGGAA TTCCTGT@  
4 GATA3 0.988 TGATAG CTATCA@  
5 FOXC1 0.955 TGTGAGTA TACTCACA@ 
6 SPIB 1.000 AGAGGAA AGAGGAA 
7 SPI1 0.978 AGGAAG CTTCCT@  
8 GATA3 0.959 AGATTG AGATTG 
9 RUNX1 0.964 TCTGTGGTT AACCACAGA@  
10 GATA2 1.000 GGATA TATCC@  
11 FOXL1 0.964 TTGACATA TTGACATA 
12 §FOXC1* 0.958 ACAAAGTA ACAAAGTA 
13 HAND1 0.968 AGTCTGGCAT ATGCCAGACT@  
14 GATA3 0.959 AGATTG CAATCT@  
15 SPI1 0.978 AGGAAG CTTCCT@  
16 ¢GATA3* 0.988 TGATAG CTATCA@  
17 SPI1 0.978 AGGAAG AGGAAG 
18 SPI1 0.978 AGGAAG AGGAAG 
19 SPI1 0.978 AGGAAG CTTCCT@  
20 RUNX1 1.000 TTTGTGGTT TTTGTGGTT 
21 IRF1 0.978 GAAAATGAAACC GAAAATGAAACC 
22 RUNX1 0.954 ACTGTGGTC ACTGTGGTC 
*TFBS (Transcription Factor Binding Site with SNP), @Reverse complement 
sequence. §-742, ¢-624, these positions are the same in (Figures 5.22-24). 
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5.2.2 In vitro analysis 
In the present study, we elucidate for the first time, the existence of IDO 
promoter variants that may play a significant role in the therapy induced side effect. 
Since our aim was to identify polymorphisms transcriptional activities of the IDO 
promoter and contribute to the reduced or increased IDO expression, the variants 
investigation was limited to the 1.3 kb of the IDO promoter, which has been shown to 
be active in reporter-gene assays.  
A 1.3 kb fragment of human genomic DNA was obtained by PCR and 
subsequently cloned into a pGL4.10 basic vector. Plasmids containing the 8 genetic 
variants were created to study their effects on the promoter activity. The cell lines 
used for these studies were the human HEK293 and SkBr3 cells. The SkBr3 cells 
were chosen because they consistently express high levels of IDO [Cao unpublished 
data]. In contrast, the HEK293 cells express very little IDO. The use of these two 
different cell lines may provide important transcription factors patterns that may 
reveal different effects of the genetic variants. 
Using the 1.3 kb IDO promoter, we have provided evidence that this promoter 
fragment drives expression of luciferase reporter constructs. This is shown in two 
human cell lines and at base line, as well as after interferon exposure. Differential 
regulation of IDO promoter in SkBr3 and HEK293 cells were assessed. IDO 
promoter activity was tested by luciferase reporter gene assay. Reporter gene 
transfection efficiencies were corrected by dividing firefly luciferase activity with 
Renilla luciferase activity. 
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Sequence analysis in the JASPAR database has shown that the -742 A/G 
interrupts FOXC1 site and -624 A/G interrupts one of the putative GATA3 box sites. 
These variants did not affect the luciferase activity compare to the wild type in both 
cells types tested (Figures 5.24 and 5.25). Three of the newly identified variants        
(-1113 G/T, -1135 C/T, -1144 C/G) were in linkage disequilibrium and formed a 
single haplotype containing the rare alleles. We only identified these three variants in 
the African American population (Table 5.5). The 3 SNP and -1144 constructs 
reduced luciferase activity dramatically in HEK293 cells after interferon gamma 
exposure (Figure 5.24). On the other hand, in SkBr3 cells there was a decrease in 
luciferase activity with constructs -1081 and 3SNP compared to the wild type (Figure 
5.25). These data suggest the presence of important element located in around -1080 
to -1144. The 3 SNP is the only construct that reduced promoter activity in both 
HEK293 and SkBr3 cells by more than 50% compare to the wild type. This indicates 
that these SNPs lie in a portion of the promoter that is important for promoter activity. 
All constructs show a dose dependent increase in promoter activity with increase 
interferon gamma dose (Figures 5.24 and 5.25). No difference in promoter activity 
detected using the constructs with SNPs at position -1081, -724, -624, -89 at base and 
after interferon gamma treatment compared to the wild type in the HEK293 cells. 
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Figure 5.24 Functional analyses of SNPs in the IDO 5’-flanking region of IDO using 
luciferase reporter assay in HEK293 cells. Average levels of luciferase activity for 
IDO 5’-flanking region reporter constructs transfected into HEK293 cells. The 
constructs have been labeled with respective SNPs to indicate the polymorphic 
nucleotide position numbered with respect to the translation start site. Bars represent 
the average of at least three independent transfection each done in triplicate (mean ± 
SD). *(p < 0.05) and ** (p < 0.05), represents data that are significantly different 
from the value obtained for the wild type compared with other variants. 
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Figure 5.25 Functional analyses of SNPs in the IDO 5’-flanking region of IDO using 
aluciferase reporter assay in SkBr3 cells. Average levels of luciferase activity for IDO  
5’-flanking region reporter constructs transfected into SkBr3 cells are depicted. The 
constructs have been labeled with respective SNPs to indicate the polymorphic 
nucleotide position numbered with respect to the translation start site. Bars represent 
the average of at least three independent transfection each done in triplicate (mean ± 
SD). * (p < 0.05), significantly different from the value obtained for the wild type 
compared with other variants. 
 
Functional analysis of constructs containing different variants in the 5’-
flanking region demonstrated a variable profile of promoter activity; this was evident 
at base line and after interferon treatment. In fact, there was suggestive evidence for a 
significant decrease in luciferase activity of the constructs that carry 3-SNP  
(-1104, -1113 and -1135) compared with the wild type. This suggests that SNPs may 
play a significant role in IDO expression. On the other hand, in HEK293 cells, when 
compared to the SkBr3 cells the promoter activity was constant and low from all 
constructs. Luciferase activity in SkBr3 cell lines is several folds higher than the 
HEK293 cells.  
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The data obtained from the promoter construct transfections were consistent in 
the IDO expression in the two human cell lines used. This difference in IDO 
expression suggests that cell-specific mechanisms regulate transcription of this gene. 
Since it is known that IDO is highly expressed in SkBr3 cells, the high luciferase 
activity in these cells could be due to the expression of transcription factors that are 
important for IDO expression. In contrast, the HEK293 cells may express relatively 
low levels of these transcription factors. 
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CHAPTER 6 
DISCUSSION 
 
To our knowledge, no effect of IDO variants on tryptophan metabolism has 
been reported to date. We have identified naturally occurring genetic variants in the 
coding and 5’-flanking region of indoleamine 2, 3-dioxygenase (INDO) gene that 
cause impaired functional activity. The existence of these alleles in the Coriell 
diversity panel subjects indicate that the variants occur in the general population. 
Although we observed genetic variants in both Caucasian and African American 
samples, the impaired function alleles in the coding and promoter region were 
detected exclusively in the African American subjects. Since our sample size was 
relatively small, it remains possible that these variants also exist in Caucasian 
populations and in other ethnic groups. Within the African American samples, ~4% 
of the subjects carried a nonfunctional INDO allele.  
The reduced function alleles included the Arg77His in exon 3 and the 9 bp 
deletion in exon 7. A number of the other genetic variants are also in important 
functional sites, such as those in the exon-intron splice junctions, and may also have 
important functional effects. These will require additional studies and are the focus of 
ongoing research. In addition, large number of SNPs that occur in the non-protein 
coding regions of a gene (e.g. 5’-flanking region), have also been analyzed in this 
work. Non-protein coding region SNPs (e.g. intronic) are likely to affect the level of 
gene expression to various extents, but an understanding of their mechanisms of 
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influence is still very incomplete. In silico methods for predicting the functional 
impact of these types of SNPs are currently under development.  
Two SNPs of the SNPs that we identified encode Ala4Thr and Arg77His amino 
acid changes. Sequence comparison demonstrates that Ala at amino acid position 4 is 
not conserved in INDO among the Dog, Mouse, Rat and Cow (Table 5.2). Since this 
amino acid resides within the N-terminal sequence of the protein, it might be part of 
the cytosolic signaling sequence of the protein. Consistent with it being a signal 
sequence, it is also missing from the crystal structure. As shown in a number of 
experiments the Ala4Thr variant did not affect IDO expression/activity. In contrast to 
the Ala4Thr, the Arg77His is conserved in IDO among the Dog, Mouse, Rat and Cow. 
These analyses predicted that the amino acid sequence at position 77 would be 
important for IDO activity. Our laboratory data confirmed this prediction. The 
absence of functional changes in Ala4Thr is consistent with findings in both Cos-7 
and HEK293 cells transfected with variant IDO cDNA. Therefore, Ala4Thr allele is 
unlikely to cause significant interindividual differences in tryptophan metabolism. We 
did not find a noticeable difference in tryptophan metabolism between wild type and 
Ala4Thr variant allele. Interestingly, we observed a minor increase in activity and 
expression of Ala4Thr variant protein in HEK293 cells.  
In the current work, tryptophan was used as a substrate for IDO kinetics. IDO 
may have several substrates 150, but tryptophan is the primary one. Therefore, 
tryptophan is normally used as the substrate in the IDO enzyme assay. We observed 
differences in the rates of tryptophan metabolism between the wild type and Arg77His  
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variant (Table 5.4). The Arg77His variant displayed a lower level of immunoreactive 
protein (Figure 5.11). Our data suggested that Arg77His amino acid variant might 
contribute to both the altered intrinsic property of the enzyme and expression of 
protein.  
Genetic variants that alter the amino acid sequence of a gene product may 
affect the cellular phenotype at various levels. They may directly alter the stability of 
the native protein structure and the folding rate, resulting in a reduced concentration 
of the protein 151. Polymorphisms residing in the substrate recognition site may 
further affect protein interactions and other biochemical activities inside the cell 152. 
Effects at the level of transcription, translation as well as post-translational 
modification can also occur. In our studies, we have begun to elucidate these 
mechanisms for the INDO variants. In vitro data are of particular importance for rare 
variations where large groups of people are not available for further investigation. 
Functional studies are also valuable for studying various mechanisms of altered 
enzyme function. Furthermore, they can improve our current understanding of the 
variable IDO expression and activity in the molecular level.  
We have yet to identify any subjects that have two nonfunctional alleles. This 
may be a result of the low frequency of these genetic variants; however, it is also 
possible that having two nonfunctional alleles may cause sufficiently impaired 
immune function to result in a high susceptibility to a variety of immunity related 
diseases. If this is the case, it is unlikely that those people would have been included 
in the Coriell DNA samples, since these are people who do not have any known  
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diseases at the time of DNA sample collection. Since IDO activity appears to be 
involved in the maintenance of pregnancy, it is also possible that homozygosity for 
the reduced activity alleles is embryonic lethal 153. However the newly identified 
INDOL1 like enzyme may compensate for reduced IDO activity. Although the INDO 
knockout is not lethal in transgenic mice 19, 154, the effect may differ in humans. In 
humans, which may involve a much greater immune response to the paternal 
antigens. In addition, compared to mice that are raised in clean animal laboratories, 
humans are also exposed to a large diversity of environmental pathogens.  
The functional effects of the Arg77His and the 9 bp deletion could be due, at 
least in part, to reduce IDO protein concentrations. For other proteins, the altered 
folding of variant proteins, and consequently, recognition by the proteasomal 
degradation pathway has been shown to cause reduced protein levels 145. This is 
often the result of rapid variant protein degradation through a proteasome-mediated 
process145. Studies on other genes indicate that this is a common mechanism of 
reduced enzyme activity caused by genetic variants. Our results showing that 
immunoreactive IDO protein is reduced in cells transfected with variant INDO 
cDNAs (Arg77His and the 9 bp deletion) are consistent with this mechanism. Since 
we observed reduced activity in the variants when they were expressed from three 
different plasmid constructs, this would seem unlikely to be caused by problems 
with the variant expression vectors. Furthermore, the variability in the IDO mRNA 
concentrations did not appear to be large enough to cause the large difference in 
amounts of protein and enzyme activity. Consistent results with both an anti-IDO  
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antibody, as well as with the anti-HA-tag antibody, indicate that the lack of 
immunoreactive protein is unlikely to be due to an altered immunogenicity of the 
variant proteins.  
Our results indicate that the Arg77His variant also affects the IDO enzyme 
kinetics. Compared to the wild type IDO, the Vmax for the Arg77His variant was 
reduced by ~60%. The Arg77His Km appeared to be slightly increased. The Km of IDO 
extracted from human placenta has been estimated to be 24.6 μM 20. This is similar to 
the wild type IDO transiently expressed in HEK293 cells 18.0 μM. The Km of the 
Arg77His variant was estimated to be slightly higher 29.6 μM. When the Vmax and Km 
were combined to calculate the intrinsic clearance, the Arg77His was substantially 
reduced (Table 5.4).  
As shown in (Figure 5.11) the expression level of Arg77His can not account 
for the difference between the wild type and variant IDO’s. One mechanism that may 
be responsible for the decreased levels of variant IDO enzyme activity is a decrease in 
the quantity of enzymatically active protein (holoenzyme).  
At present, little is known about translational and posttranslational regulation 
events involved in the IDO protein. It is known that the incorporation of the heme 
prosthetic group is a required posttranslational regulation step 155, 156. Our studies now 
indicate that alternations in the heme incorporation into IDO may be affected by 
genetic variants in the INDO gene. Exposing cells with heme analog, hemin increased 
IDO activity in the Arg77His DO variant; it is most likely by increasing the amount of 
holoenzyme (Figures 5.16, 5.18-21). The effect of hemin in IDO activity was first  
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obsereved in the cell free expression system in which cells were treated with 20 μM 
hemin (Figure 5.14). The effect of hemin was negligible in the wild type and Ala4 
variant (Figure 5.14). It is possible that the exogenous hemin added into this system 
might increase the proportion of holo to apo Arg77His variant protein ratio in the 
system and resulted in increase kynurenine formation. A previous study has shown 
that addition of hemin to IFN-γ activated human monocyte derived macrophages 
(hMDM) culture and cell lysate prepared from this activated cells increased formation 
of kynurenine 157. These data suggested that cellular heme may be the limiting for 
IDO activity. As a consequence, a significant amount of IDO expressed in the cells 
may be present as apoenzyme 157. The concentration of heme in HEK293 cells was 5-
fold higher than in cells that do not transfected with the neuronal nitric oxide synthase 
(nNOS) cDNA 158. These data are consistent with our findings which showed several 
fold higher heme concentration in cells transefcted with wild type IDO compared to 
pcDNA3 transfected cells (Figure 5.19). Although the major portion of cellular heme 
is probably associated with heme containing proteins, it is generally assumed that 
cells contain low levels of free heme (unbound) 158, 159. It should be pointed out that 
heme homeostasis is tightly regulated in a cell and heme oxygenase (HO) is the only 
physiological mechanism of heme degradation 159, 160.  
The inhibition of heme synthesis by SA was shown to reduce IDO activity in 
the wild type and profoundly blocked in the Arg77His variant (Figure 5.19). This 
indicates that the availability of heme is important for IDO activity. The reversing of 
the SA effect by hemin indicates that hemin can apparently substitute for the  
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endogenous heme (Figures 5.19 and 5.21). Furthermore, our studies with other 
proteasome inhibitors and lysosomal inhibitors did not restore enzyme activity 
(Figure 5.17 and 5.18). This suggests that the Arg77His may have a defect in 
incorporating heme and it may exist as an apoenzyme; however, the 9 bp deletion 
may be degraded through other mechanisms. In the light of this tight heme regulation, 
and the fact that heme concentrations in cells transfected with variant IDO constructs 
were low, we hypothesized that the heme degradation is accelerated or heme 
synthesis is slowed in this cells due to less incorporation into IDO. Future studies 
assessing the level of heme oxygenase (HO) expression in cells transfected with 
Arg77His will help to distinguish between these possibilities.  
Some insight into the effects of the variants on the IDO protein may be 
provided by the examination of the 3D structure of the IDO protein. First, based on 
the crystal structure of the IDO protein, these amino acids affected by the genetic 
variants do not appear to directly contact the substrate or the heme moiety; however, 
they may indirectly affect the structure of one of these domains. Secondly, since the 
positions of the mutations appear to be on the surface of the enzyme, the variant 
proteins may be easily identified by the cellular degradation machinery. Furthermore, 
since the variant amino acids are on the surface of the protein, it is possible that they 
interfere with protein-protein interactions. Although these amino acids could be 
involved in protein-protein interactions, little is known about IDO’s binding partners, 
making it difficult to speculate further on this potential mechanism.  
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Specific Aim 2: 
This thesis provides a new promoter polymorphisms of the INDO gene for 
which its functionality was demonstrated in vitro. The variable induction by 
interferon gamma due to variants in the 5’-flanking region is also assessed. In order to 
understand the effect of SNPs in INDO gene promoter activity, we have cloned 1.3 kb 
of INDO promoter covering a number of important transcription factor binding sites. 
In this thesis, we have identified and described the allele frequencies for eight INDO  
promoter variant by resequncing the 5’-flanking region of INDO promoter. The 
distributions of these alleles were described in the African American and Caucasian 
population. Eight of the SNPs at positions (-1144, -1135, -1113, -1104, -1081, -742, 
 -624 and -89) relative to the translation start site have never been reported before. 5’-
flanking region of INDO gene contain several interesting structural and potential 
regulatory elements. For example, with in the 1.3 kb region using JASPAR 22 
putative transcription binding consensus sequences were predicted at 95% threshold. 
Two of the newly identified SNPs are located in (FOXC1 at -742 and GATA3 at -624) 
TFBS. The functionality of all variants were tested in vitro in two different cell lines, 
and only one of them (-1144, -1135, -1113) was shown to influence the transcription 
activity of the reporter gene in both SkBr3 and HEK293 cells. Based on the in vitro 
functional reporter assay, results the 3-SNP variant (designated as haplotype in this 
study) leads to a considerable reduction in the transcriptional activity of the reporter 
gene in both cell lines tested after interferon gamma exposure (Figures 5.24 and 5.25). 
The -1081 variant showed reduction of promoter activity only in SkBr3 cells at high 
dose of interferon gamma (Figure 5.25). Most of factors that bind to these regions 
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remain to be identified and characterized. Two of the SNPs described in this study are 
localized within the FOXC1, -742 and GATA3,-624. These sites have been shown to 
play an important role in the transcription of a wide variety of eukaryotic genes 161, 162. 
In vitro functional analysis using a luciferase reporter construct carrying a variant in 
FOXC1and GATA3 sites reveled no reduction in the transcription level of luciferase 
reporter gene at base line and after interferon exposure (Figures 5.24 and 5.25). 
Furthermore, during TFBS analysis using a sequence with these two SNPs at (-742 
and -624) the outcome did not include FOXC1and GATA3. One possibility is the 
prediction was wrong or the model system we used is not ideal to test the effect of 
these variants. 
We have identified and characterized IDO promoter variants that played a 
significant role in regulating the expression of human IDO. IDO gene have been 
cloned and sequenced revealing transcriptional promoter elements (GAS and ISRE 
motifs) that confer responsiveness to interferons via the JAK-STAT signaling 
pathway 163. Mutagenesis experiments revealed the importance of these motifs for the 
interferon mediated IDO induction and it was also recognized by a putative cellular 
specific regulatory transcriptional factor(s) ISRE and GAS 164. 
IDO is one of the enzymes that is able oxidize tryptophan into kynurenine, 
which may be an important defense mechanism against pathogens. In addition, the 
transcriptional regulation of IDO might have potential significance in therapy induced 
increased IDO expression. It has been reported that levels of IDO transcript, protein  
and its primary metabolite increased in patients treated with interferon 81, 165. The 
mechanisms underlying the interindividual variations in IDO expression is remain 
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unknown. Future studies will be required to determine whether the variable IDO 
expression is a cause or an effect of the variable outcomes.  
The variants we have identified may have phenotypic effects in the human 
population. Since many preclinical studies indicate that IDO frequently induces 
immune tolerance 166-168, people with genetically reduced IDO activity may be at an  
elevated risk for inflammatory and autoimmune type diseases. As described above, 
maternal tolerance of paternal antigens may also be affected. Natural killer (NK) 
cells play a significant role in immune responses to pathogenic agents as well as in 
the defense against cancer cells 169. The mechanisms underlying NK cell recognition 
of target cells have been studied in great detail. In contrast to the potential effects on 
tolerance, other preclinical studies indicate that NK cell activity is partially 
dependent on IDO activity 169, 170. Consequently, people with reduced IDO activity 
may have impaired immune function and have an increased susceptibility to 
infectious diseases. Since there does not appear to be redundancy of tryptophan 
metabolizing enzymes that are induced in peripheral tissues by inflammation, it is 
likely that people with no functional INDO alleles would have phenotypic 
consequences. These phenotypes would likely be revealed to a greater extent in 
human populations that are exposed to many pathogenic antigens than in INDO 
knockout mice that are housed in relatively clean environments. These genetic 
variants may also contribute to inter-individual variability in IDO expression/activity  
 
We hypothesized that patients who are treated with interferon based therapy 
and have the 3-SNPs, would have reduced IDO induction compared with wild type 
alleles. Although, these variants are not widely distributed in the population and 
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occurs in approximately 3% (allelic frequency) of the African American population, it 
is important to note who is benefiting from this therapy and minimize therapy  
induced side effects. In addition, the interindividual variability of therapy outcomes 
and IDO expression is undoubtedly multi factorial. Therefore a large study would be 
needed to confirm possible relationship between the 3-SNPs and interferon therapy 
outcome. An understanding of the impact of these 3-SNPs and interferon therapy will 
be valuable information. 
An interesting finding from our study is the higher prevalence in African 
Americans. These data raise the question of their potential contribution to clinical 
disease in this population. Since a key function of IDO is to down regulate T-cell 
immunity, it is interesting to speculate that these variants may have a role in diseases 
highly prevalent in African Americans, such as asthma or type I diabetes. Since the 
sample size was modest and the frequencies of each of these individual variants were 
low, it will be important to conduct larger studies to accurately determine the allelic 
frequencies in the different ethnic populations. The work described in this thesis 
provides a foundation for future studies addressing the association between IDO 
genotype and clinical response to drugs (interferons) and a firm basis to allow 
impaired mechanistic understanding of the interaction between tryptophan 
metabolism and theraputics. These questions will be addressed in future studies.  
 
In summary, we have identified and described the allele frequencies for IDO 
coding and promoter variants in the African American and Caucasian population. We 
have assessed the functional significance of three coding and eight promoter variants. 
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This is the first report on the identification of allelic variants of the INDO gene in 
these two populations combined with functional data. In the African American  
population a total 18 alleles were identified, including the four functional variants 
(two in the promoter and two in the coding region). These four functional variants 
were not identified in the Caucasian population.  
 
Future studies 
 More research needs to be conducted to clarify the functional consequences of 
known IDO genetic variant and their impacts on human health. As additional 
information about the biological and physiological functions of the gene is gathered, 
un understanding of the role of IDO polymorphisms will also increase. In this context 
it will be important to consider the possible complexity of interactions between 
different polymorphisms; especially in genes at different steps and different pathways 
that are involved in IDO regulation.   
In the future, it would be valuable to further evaluate the functional significance 
of these IDO variants in vivo in studies such as the following: 
 
1. Determine whether IDO activity in human tissues or cells associated with the 
genetic variants in the INDO gene.  
 
2. Determine the association of INDO genetic variants in disease susceptibility; 
populations to focus on would be those with disease such as autoimmune and 
cancer? 
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3. Determine if interferon responses are different between the groups of people 
with different INDO geneotypes. Afirst step would be to conduct haplotype 
analysis using all known INDO variants. Subsequently, it would be appropriet 
to test haplotype-phenotype associations for common IDO haplotypes under 
baseline conditions and after interferon treatment. 
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CHAPTER 7 
CONCLUSIONS 
 
The current study has examined genetic factors that have the potential to the 
variability in IDO enzyme expression and activity. We have investigated genetic 
factors that may contribute to IDO interindividual variability at three levels. 
A. By the resequencing, identification and characterization of INDO genetic 
variants in the coding and promoter regions. 
B. By predicting functional significance of INDO variants in silico. 
C. By determining the functional effects of INDO variants in vitro.  
We conclude the following: 
? There are naturally occurring genetic variants in the human population that 
result in altered enzyme function. The Arg77His (exon 3) and the exon 7 (9 bp 
deletion) variants are examples of reduced functional alleles.  
? The Ala4Thr variant exhibited similar metabolism and substrate affinity 
towards tryptophan (Vmax and Km) as the wild type. 
? The Arg77His (exon 3) variant protein does not appear to be degraded through 
the proteasomal and lysosomal pathway. 
? Transfection of HEK293 cells with wild type IDO cDNA increases cellular 
heme concentrations; however, this increase is much less when the cells are 
transfected with impaired function Arg77His and 9 bp deletion variants. 
? In the wild type cells, the inhibition of heme synthesis substantially reduced 
the IDO activity. In the Arg77His cells, the SA completely abolished the 
formation of kynurenine.  
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? We have identified seven novel genetic variants in the 5’-flanking region of 
INDO gene. 
? Two of the novel SNPs are located with in the putative transcription factor 
binding sites FOXC1 and GATA3. 
? All constructs show a dose dependent increase in promoter activity with 
increase interferon gamma dose.  
? The 3-SNP haplotype and -1144 constructs reduced luciferase activity in 
HEK293 cells after interferon gamma exposure.  
?  Our data suggest the presence of important element around -1080 to -1144 bp 
of INDO promoter. 
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